JP2008024704A - Composition having hyaluronic acid production-promoting ability and/or fibroblast proliferation-promoting ability - Google Patents
Composition having hyaluronic acid production-promoting ability and/or fibroblast proliferation-promoting ability Download PDFInfo
- Publication number
- JP2008024704A JP2008024704A JP2007165686A JP2007165686A JP2008024704A JP 2008024704 A JP2008024704 A JP 2008024704A JP 2007165686 A JP2007165686 A JP 2007165686A JP 2007165686 A JP2007165686 A JP 2007165686A JP 2008024704 A JP2008024704 A JP 2008024704A
- Authority
- JP
- Japan
- Prior art keywords
- group
- acid
- composition
- retinol
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 45
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 45
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 45
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 24
- 108090001109 Thermolysin Proteins 0.000 claims abstract description 45
- 239000007857 degradation product Substances 0.000 claims abstract description 30
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 25
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 17
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 100
- 235000020944 retinol Nutrition 0.000 claims description 56
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 51
- 229960003471 retinol Drugs 0.000 claims description 47
- 239000011607 retinol Substances 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000035755 proliferation Effects 0.000 claims description 14
- 230000002207 retinal effect Effects 0.000 abstract description 14
- -1 ester derivative of retinoic acid Chemical class 0.000 description 86
- 244000068988 Glycine max Species 0.000 description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 235000010469 Glycine max Nutrition 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 229930002330 retinoic acid Natural products 0.000 description 18
- 229960001727 tretinoin Drugs 0.000 description 18
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 10
- 230000002087 whitening effect Effects 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 239000004359 castor oil Substances 0.000 description 8
- 235000019438 castor oil Nutrition 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 8
- 229940001941 soy protein Drugs 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 229960000458 allantoin Drugs 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000003381 solubilizing effect Effects 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 4
- 241001474374 Blennius Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 4
- 241000546188 Hypericum Species 0.000 description 4
- 235000017309 Hypericum perforatum Nutrition 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 241000237502 Ostreidae Species 0.000 description 4
- 235000004347 Perilla Nutrition 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000005215 alkyl ethers Chemical class 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 150000002772 monosaccharides Chemical group 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 150000002482 oligosaccharides Polymers 0.000 description 4
- 235000020636 oyster Nutrition 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 229960000342 retinol acetate Drugs 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 235000019173 retinyl acetate Nutrition 0.000 description 4
- 239000011770 retinyl acetate Substances 0.000 description 4
- 235000019172 retinyl palmitate Nutrition 0.000 description 4
- 239000011769 retinyl palmitate Substances 0.000 description 4
- 229940108325 retinyl palmitate Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001116389 Aloe Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 235000011960 Brassica ruvo Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 235000008597 Diospyros kaki Nutrition 0.000 description 3
- 244000236655 Diospyros kaki Species 0.000 description 3
- 235000011201 Ginkgo Nutrition 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 241000208422 Rhododendron Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 235000019169 all-trans-retinol Nutrition 0.000 description 3
- 239000011717 all-trans-retinol Substances 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 239000010975 amethyst Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 125000006606 n-butoxy group Chemical group 0.000 description 3
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 241000193389 Bacillus thermoproteolyticus Species 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 241000269333 Caudata Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 241000544061 Cuculus canorus Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- 244000061408 Eugenia caryophyllata Species 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 241000208690 Hamamelis Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 244000025221 Humulus lupulus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 244000062780 Petroselinum sativum Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 235000010913 Picrasma quassioides Nutrition 0.000 description 2
- 240000004659 Picrasma quassioides Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229940100609 all-trans-retinol Drugs 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960002350 guaiazulen Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 2
- 125000002951 idosyl group Chemical group C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 2
- 229960001669 kinetin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 150000002948 pantothenic acids Chemical class 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 235000011197 perejil Nutrition 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 229960001325 triclocarban Drugs 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000009538 yokuinin Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 1
- BDMPVVYWKWCNKK-SHGBQBHBSA-N (2e,4e,6e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6-trienal Chemical compound O=C\C=C(/C)\C=C\C=C(/C)CCC1=C(C)CCCC1(C)C BDMPVVYWKWCNKK-SHGBQBHBSA-N 0.000 description 1
- XLRQASJLHKRLKG-JVSJJYLASA-N (2e,4e,6e,8e)-3,7-dimethyl-9-(1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl)nona-2,4,6,8-tetraen-1-ol Chemical compound C1CCC(C)(C)C2(/C=C/C(/C)=C/C=C/C(=C/CO)/C)C1(C)O2 XLRQASJLHKRLKG-JVSJJYLASA-N 0.000 description 1
- UREHIXRTGAZOND-OVSJKPMPSA-N (2e,4e,6e,8e)-3,7-dimethyl-9-(2,2,6-trimethylcyclohexyl)nona-2,4,6,8-tetraenal Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C=O UREHIXRTGAZOND-OVSJKPMPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JSSKAZULTFHXBH-UHFFFAOYSA-N 1-O-Tetradecylglycerol Chemical compound CCCCCCCCCCCCCCOCC(O)CO JSSKAZULTFHXBH-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- ZONJATNKKGGVSU-UHFFFAOYSA-N 14-methylpentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCC(O)=O ZONJATNKKGGVSU-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- LRZBIPQJHILPJI-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(2,3-dihydroxypropyl)octadecanoate Chemical compound CCCCCCCCCCCCCCCCC(CC(O)CO)C(=O)OCC(O)CO LRZBIPQJHILPJI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- FQCSIUSICFAMDD-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid;sodium Chemical compound [Na].OC(=O)N1CCCC1=O FQCSIUSICFAMDD-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QHNVWXUULMZJKD-UHFFFAOYSA-N 3,4-didehydroretinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C QHNVWXUULMZJKD-UHFFFAOYSA-N 0.000 description 1
- JAUFWPNLLLUYNV-UHFFFAOYSA-N 3-(16-methylheptadecoxy)propane-1,2-diol Chemical compound CC(C)CCCCCCCCCCCCCCCOCC(O)CO JAUFWPNLLLUYNV-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- RVSTWRHIGKXTLG-WCXIOVBPSA-N Pangamic acid Chemical compound CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RVSTWRHIGKXTLG-WCXIOVBPSA-N 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 1
- 240000005893 Pteridium aquilinum Species 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 244000079529 Pyrus serotina Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 1
- 244000155437 Raphanus sativus var. niger Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- RIQIJXOWVAHQES-UNAKLNRMSA-N Tocoretinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-UNAKLNRMSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- MPACCMIQWWLTLS-DBIMOSKASA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] cyclopentanecarboxylate Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/COC(=O)C1CCCC1 MPACCMIQWWLTLS-DBIMOSKASA-N 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- ZQHDBIHAVWMCHD-UHFFFAOYSA-N [2-hydroxy-3-[3-[3-[3-[3-[3-[3-[3-[3-(2-hydroxy-3-octadecanoyloxypropoxy)-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]-2-octadecanoyloxypropoxy]propyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(COCC(COCC(COCC(COCC(COCC(COCC(COCC(COCC(O)COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC ZQHDBIHAVWMCHD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 description 1
- ZGISOPBIAXHOTQ-OUGXGHBNSA-N all-trans-retinyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C ZGISOPBIAXHOTQ-OUGXGHBNSA-N 0.000 description 1
- QLFIHDFIMGLXEA-XOEOKOMISA-N all-trans-retinyl heptanoate Chemical compound CCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QLFIHDFIMGLXEA-XOEOKOMISA-N 0.000 description 1
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 description 1
- FXKDHZXYYBPLHI-TUTABMRPSA-N all-trans-retinyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FXKDHZXYYBPLHI-TUTABMRPSA-N 0.000 description 1
- YNGACJMSLZMZOX-FPFNAQAWSA-N all-trans-retinyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C YNGACJMSLZMZOX-FPFNAQAWSA-N 0.000 description 1
- 125000003525 allosyl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 125000003420 altrosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- LDHQCZJRKDOVOX-IHWYPQMZSA-N isocrotonic acid Chemical compound C\C=C/C(O)=O LDHQCZJRKDOVOX-IHWYPQMZSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- KEMQGTRYUADPNZ-UHFFFAOYSA-M margarate Chemical compound CCCCCCCCCCCCCCCCC([O-])=O KEMQGTRYUADPNZ-UHFFFAOYSA-M 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940057061 mevalonolactone Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940069825 okra extract Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055705 pangamic acid Drugs 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 125000004024 talosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、ヒアルロン酸産生促進能を有する有用な新規組成物、線維芽細胞増殖促進能を有する有用な新規組成物、並びにそれらに関連する発明に関する。 The present invention relates to a useful novel composition having the ability to promote hyaluronic acid production, a useful novel composition having the ability to promote the proliferation of fibroblasts, and an invention related thereto.
従来より、動物の結合組織には、その主要成分として、コラーゲン、ヒアルロン酸、エラスチン、コンドロイチン硫酸、ヘパラン硫酸、デルマタン硫酸、ラミニンなどが含まれていることが分かっている。なかでもヒアルロン酸は、結合組織において後述のような重要な役割を果たしている。 Conventionally, it has been known that connective tissues of animals contain collagen, hyaluronic acid, elastin, chondroitin sulfate, heparan sulfate, dermatan sulfate, laminin and the like as main components. Of these, hyaluronic acid plays an important role in the connective tissue as described below.
ヒアルロン酸は、皮膚、軟骨、関節液、臍帯、眼硝子体、その他の結合組織に存在する酸性ムコ多糖の一種である。ヒアルロン酸は生体内において多様な役割を担っていることで知られ、例えば、ヒアルロン酸は関節液の主成分として、関節においてクッションの役目を果たしたり、磨耗した軟骨を修復する機能を有することが知られている。またヒアルロン酸は、生体内において抗炎症作用を有することも知られている。 Hyaluronic acid is a kind of acidic mucopolysaccharide present in skin, cartilage, joint fluid, umbilical cord, ophthalmic vitreous, and other connective tissues. Hyaluronic acid is known to have a variety of roles in the body. For example, hyaluronic acid is a main component of joint fluid, and serves as a cushion in joints and has a function of repairing worn cartilage. Are known. Hyaluronic acid is also known to have an anti-inflammatory effect in vivo.
さらに皮膚表皮では、基底層から顆粒層まで広くヒアルロン酸が分布しており、表皮細胞外空間の構造を支え、表皮基底層から角層への栄養分・老廃物などの物質輸送に関与したり、表皮細胞のターンオーバーを促進するトリガーとして働いたりすることが知られている。また、ヒアルロン酸は、わずか1gで約6Lもの水分を保持できるという強力な保水作用を有し、その作用により、細胞間隙に水分を保持する役割を担っていることも知られている。ヒアルロン酸は、加齢により徐々に減少することが知られ、この減少が、皮膚のシワやタルミの形成、皮膚の弾力性やハリの低下、または皮膚の乾燥や肌荒れといった皮膚の老化を招く一因となっている。 Furthermore, in the skin epidermis, hyaluronic acid is widely distributed from the basal layer to the granular layer, supporting the structure of the extracellular space of the epidermis, involved in the transport of substances such as nutrients and waste products from the epidermal basal layer to the horny layer, It is known to act as a trigger to promote epidermal cell turnover. It is also known that hyaluronic acid has a strong water-retaining effect that can hold as much as about 6 L of water with only 1 g, and has a role of holding water in the cell gap by that action. Hyaluronic acid is known to gradually decrease with age, and this decrease may lead to the formation of skin wrinkles and tarmi, skin elasticity and elasticity, or skin aging such as skin dryness and rough skin. It is a cause.
以上のような理由から、加齢等の原因により減少したヒアルロン酸の量を補充・増大させることが望まれているが、ヒアルロン酸は高分子化合物であるため、皮膚の外側から生体内に供給することは容易ではない。従って、生体内(例えば、表皮細胞間)などにヒアルロン酸を供給するためには、生体内におけるヒアルロン酸の生合成の促進が重要とも言われている。 For these reasons, it is desirable to supplement and increase the amount of hyaluronic acid that has decreased due to aging, etc., but since hyaluronic acid is a polymer compound, it is supplied to the living body from outside the skin. It is not easy to do. Therefore, in order to supply hyaluronic acid in vivo (for example, between epidermal cells), it is said that promotion of biosynthesis of hyaluronic acid in vivo is important.
ヒアルロン酸の減少による状態を改善するために、種々のヒアルロン酸合成促進物質が見出されている。例えば、アロエ抽出物、オクラ抽出物、水溶性β−1,3−グルカン誘導体、酵母抽出物(特許文献1)、ツカサノリ科トサカモドキ属に属する海藻の抽出物(特許文献2)、ラベンダー抽出物(特許文献3)、ダービリア科ダービリア属に属する海藻の抽出物(特許文献4)、レチノイン酸等が知られている。 Various hyaluronic acid synthesis promoting substances have been found to improve the state caused by the reduction of hyaluronic acid. For example, aloe extract, okra extract, water-soluble β-1,3-glucan derivative, yeast extract (patent document 1), seaweed extract belonging to the genus Tokamodori (patent document 2), lavender extract ( Known are Patent Document 3), extracts of seaweeds belonging to the genus Davilia (Patent Document 4), retinoic acid, and the like.
また、真皮の主細胞である線維芽細胞は、上述のようなヒアルロン酸を含むムコ多糖類や、皮膚のハリを保っているコラーゲン、皮膚の弾力性を維持しているエラスチン等を産生する。ところが、紫外線の照射、空気の著しい乾燥、過度の皮膚洗浄等の外的因子の影響や、加齢により、線維芽細胞自体の増殖能力が低下し、皮膚の保湿機能や弾力性が低下し、皮膚の老化(例えば、皮膚の弾力性もしくはハリの低下や、皮膚のシワもしくはタルミ等)が加速されることが知られている。 Fibroblasts, which are the main cells of the dermis, produce mucopolysaccharides containing hyaluronic acid as described above, collagen that keeps the skin firm, and elastin that keeps the skin elastic. However, due to the effects of external factors such as ultraviolet light irradiation, drastic air drying, excessive skin washing, and aging, the proliferation ability of fibroblasts itself is reduced, and the moisture retention function and elasticity of the skin are reduced. It is known that aging of the skin (for example, reduction in elasticity or elasticity of the skin, wrinkles or sagging of the skin, etc.) is accelerated.
従って、線維芽細胞の増殖を促進することもまた、皮膚の弾力性もしくはハリの低下に対する予防及び/又は改善や、皮膚のシワもしくはタルミの予防及び/又は改善に寄与すると考えられる。
上述のような生体におけるヒアルロン酸の果たす役割の重要度に鑑み、顕著なヒアルロン酸産生促進能を有する更なる有用な新規組成物の開発が望まれている。本発明はかかる従来の問題に鑑み、顕著なヒアルロン酸産生促進能を有する有用な新規組成物を提供することを目的とする。また本発明は、線維芽細胞増殖促進能を有する有用な新規組成物を提供することを目的とする。 In view of the importance of the role of hyaluronic acid in the living body as described above, development of a further useful new composition having a remarkable ability to promote hyaluronic acid production is desired. In view of the conventional problems, an object of the present invention is to provide a useful novel composition having a remarkable ability to promote hyaluronic acid production. Another object of the present invention is to provide a useful novel composition having the ability to promote fibroblast proliferation.
本発明者らは、前記課題を解決するために鋭意検討した結果、レチノール類と、ダイズタンパク質をサーモリシンという特定のプロテアーゼで分解して得られる産物とを併用して用いることにより、レチノール類を単独で用いるよりも細胞におけるヒアルロン酸産生促進能が顕著に促進されることを見出し、また更に検討を重ねることにより、上記両成分の併用により、線維芽細胞の増殖が相乗的に促進されることをも見出し、本発明を完成させるに至った。 As a result of intensive studies to solve the above problems, the present inventors have used retinols alone by using retinols in combination with a product obtained by decomposing soybean protein with a specific protease called thermolysin. It has been found that the ability to promote hyaluronic acid production in cells is significantly promoted compared to that used in the above, and further studies have shown that the combined use of both components synergistically promotes the proliferation of fibroblasts. And the present invention has been completed.
従って、本発明は以下を提供する。
(1)(A)レチノール及びその誘導体からなる群より選択される少なくとも一種と、(B)ダイズタンパク質のサーモリシン分解物とを含有する組成物。
(2)細胞におけるヒアルロン酸産生を促進するために使用され得る、項目(1)に記載の組成物。
(3)線維芽細胞増殖を促進するために使用され得る、項目(1)又は(2)に記載の組成物。
Accordingly, the present invention provides the following.
(1) A composition comprising (A) at least one selected from the group consisting of retinol and derivatives thereof, and (B) a thermolysin degradation product of soybean protein.
(2) The composition according to item (1), which can be used to promote hyaluronic acid production in cells.
(3) The composition according to item (1) or (2), which can be used to promote fibroblast proliferation.
本発明により、顕著なヒアルロン酸産生促進能を有する有用な新規組成物が提供される。本発明の組成物は、細胞におけるヒアルロン酸産生を促進するために使用することができ、例えば、抗シワ用組成物、抗タルミ用組成物、関節障害の予防又は治療用組成物、炎症性疾患の予防又は治療用組成物などとして有益に使用することができる。また本発明により、線維芽細胞増殖促進能を有する有用な新規組成物が提供される。 The present invention provides a useful novel composition having a remarkable ability to promote hyaluronic acid production. The composition of the present invention can be used to promote hyaluronic acid production in cells. For example, an anti-wrinkle composition, an anti-tarmi composition, a composition for preventing or treating joint disorders, an inflammatory disease It can be beneficially used as a preventive or therapeutic composition. The present invention also provides a useful novel composition having the ability to promote fibroblast proliferation.
以下、本発明を詳細に説明する。なお、本明細書中において使用される用語は、特に他に言及しない限り、当該分野で通常用いられる意味で用いられていることが理解されるべきである。 Hereinafter, the present invention will be described in detail. It should be understood that the terms used in the present specification are used in the meaning normally used in the art unless otherwise specified.
本発明は、(A)レチノール及びその誘導体からなる群より選択される少なくとも一種と、(B)ダイズタンパク質のサーモリシン分解物とを含有する組成物である。 The present invention is a composition comprising (A) at least one selected from the group consisting of retinol and derivatives thereof, and (B) a thermolysin degradation product of soybean protein.
本発明に用いられる、レチノール及びその誘導体〔本明細書では、これらを総称して「レチノール類」ということがある〕は、医薬品、医薬部外品、化粧品または食品の分野において用いられ得るものであれば特に限定されない。 The retinol and derivatives thereof used in the present invention (in the present specification, these are sometimes collectively referred to as “retinols”) are those that can be used in the field of pharmaceuticals, quasi drugs, cosmetics or foods. If there is no particular limitation.
レチノール誘導体としては、レチノイン酸;レチナール;レチノール、レチノイン酸、又はレチナールの異性体;レチノール又はその異性体のエステル誘導体;レチノール又はその異性体のエーテル誘導体;レチノイン酸又はその異性体のエステル誘導体;レチノール、レチノイン酸、レチナール又はそれらの異性体のエポキシ誘導体;レチノール、レチノイン酸、レチナール又はそれらの異性体の水素原子が脱離又は水素原子が付加した誘導体;等が挙げられる。 Retinol derivatives include: retinoic acid; retinal; retinol, retinoic acid, or an isomer of retinal; retinol or an ester derivative of the isomer; retinol or an ether derivative of the isomer; an ester derivative of retinoic acid or the isomer; , Retinoic acid, retinal or their isomer epoxy derivatives; retinol, retinoic acid, retinal or their isomers with hydrogen atoms eliminated or hydrogen atoms added; and the like.
レチノール、レチノイン酸又はレチナールの異性体としては、幾何異性体(シス−トランス異性体、又はE,Z異性体)が挙げられ、二重結合の結合位置や数、その立体構造は特に限定されない。
レチノール、レチノイン酸、又はレチナールの異性体の具体例としては、レチノール、レチノイン酸又はレチナールの、全トランス体、13−シス体、11−シス体、9−シス体、7−シス体、7,9−ジ−シス体、7,13−ジ−シス体、11,13−ジ−シス体、9,13−ジ−シス体、9,11,13−トリ−シス体などがそれぞれ挙げられる。これら異性体の中でも、全トランス体または13−シス体が好ましく、全トランス体が特に好ましい。
Examples of the isomers of retinol, retinoic acid or retinal include geometric isomers (cis-trans isomers or E, Z isomers), and the bonding position and number of double bonds and the steric structure thereof are not particularly limited.
Specific examples of the isomers of retinol, retinoic acid, or retinal include all-trans form, 13-cis form, 11-cis form, 9-cis form, 7-cis form, 7, retinol, retinoic acid, or retinal form. Examples thereof include 9-di-cis isomer, 7,13-di-cis isomer, 11,13-di-cis isomer, 9,13-di-cis isomer, 9,11,13-tri-cis isomer, and the like. Among these isomers, all-trans isomer or 13-cis isomer is preferable, and all-trans isomer is particularly preferable.
レチノール又はその異性体のエステル誘導体としては、レチノール又はその異性体と、脂肪族カルボン酸、芳香族カルボン酸等の酸類とのエステルが挙げられる。 Examples of the ester derivative of retinol or its isomer include esters of retinol or its isomer with acids such as aliphatic carboxylic acids and aromatic carboxylic acids.
脂肪族カルボン酸としては、飽和又は不飽和の炭素数1〜22の脂肪族カルボン酸が挙げられ、好ましくは飽和又は不飽和の炭素数2〜18の脂肪族カルボン酸である。具体例としては、ギ酸、酢酸、プロピオン酸、酪酸、イソ酪酸、吉草酸、イソ吉草酸、ピバル酸、ヘキサン酸、ヘプタン酸、オクタン酸、オクチル酸、ノナン酸、デカン酸、ウンデカン酸、ラウリン酸、ミリスチン酸、ペンタデカン酸、パルミチン酸、イソパルミチン酸、ヘプタデカン酸、ステアリン酸、イソステアリン酸、ベヘン酸、アクリル酸、プロピオル酸、メタクリル酸、クロトン酸、イソクロトン酸、ウンデシレン酸、ミリストレイン酸、パルミトレイン酸、オレイン酸、リシノレン酸、リノール酸、リノレン酸、アラキドン酸、イコサペンタエン酸、ドコサヘキサエン酸、シクロペンタンカルボン酸、シクロヘキサンカルボン酸などの脂肪族モノカルボン酸;シュウ酸、マロン酸、コハク酸、グルタル酸、アジピン酸、ピメリン酸、スベリン酸、アゼライン酸、セバシン酸、フマル酸、マレイン酸などの脂肪族ジカルボン酸又はそのモノエステル(例、メチル、エチル、プロピル、イソプロピル、ブチル、s−ブチル、t−ブチル、イソブチル、ペンチル、ヘキシル等の炭素数1〜6のアルキルエステル等);レチノイン酸等が挙げられる。また、脂肪族カルボン酸は置換されていても良く、その置換基としては、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、プロポキシ基、イソプロポキシ基、ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、ペンチルオキシ基、ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、ヒドロキシ基等が挙げられる。
芳香族カルボン酸としては、炭素数7〜12の芳香族カルボン酸が挙げられ、好ましくは炭素数7〜10の芳香族カルボン酸である。具体例としては、安息香酸、ナフトエ酸、桂皮酸等の芳香族モノカルボン酸;フタル酸、イソフタル酸、テレフタル酸等の芳香族ジカルボン酸;等が挙げられる。また、芳香族カルボン酸は置換されていても良く、その置換基としては、炭素数1〜6のアルキル基(例、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、s−ブチル基、t−ブチル基、イソブチル基、ペンチル基、ヘキシル基等)、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、プロポキシ基、イソプロポキシ基、ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、ペンチルオキシ基、ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、ヒドロキシ基等が挙げられる。
Examples of the aliphatic carboxylic acid include saturated or unsaturated aliphatic carboxylic acids having 1 to 22 carbon atoms, preferably saturated or unsaturated aliphatic carboxylic acids having 2 to 18 carbon atoms. Specific examples include formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, hexanoic acid, heptanoic acid, octanoic acid, octylic acid, nonanoic acid, decanoic acid, undecanoic acid, lauric acid , Myristic acid, pentadecanoic acid, palmitic acid, isopalmitic acid, heptadecanoic acid, stearic acid, isostearic acid, behenic acid, acrylic acid, propiolic acid, methacrylic acid, crotonic acid, isocrotonic acid, undecylenic acid, myristoleic acid, palmitoleic acid Aliphatic carboxylic acids such as oleic acid, ricinolenic acid, linoleic acid, linolenic acid, arachidonic acid, icosapentaenoic acid, docosahexaenoic acid, cyclopentanecarboxylic acid, cyclohexanecarboxylic acid; oxalic acid, malonic acid, succinic acid, glutaric acid, Adipic acid, pimelin , Suberic acid, azelaic acid, sebacic acid, fumaric acid, maleic acid and other aliphatic dicarboxylic acids or monoesters thereof (eg, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, isobutyl, pentyl, C1-C6 alkyl esters such as hexyl); and retinoic acid. In addition, the aliphatic carboxylic acid may be substituted, and the substituent may be an alkoxy group having 1 to 6 carbon atoms (eg, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, s-butoxy group). Group, t-butoxy group, isobutyloxy group, pentyloxy group, hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), amino group, hydroxy group and the like.
As aromatic carboxylic acid, C7-12 aromatic carboxylic acid is mentioned, Preferably it is C7-10 aromatic carboxylic acid. Specific examples include aromatic monocarboxylic acids such as benzoic acid, naphthoic acid and cinnamic acid; aromatic dicarboxylic acids such as phthalic acid, isophthalic acid and terephthalic acid. In addition, the aromatic carboxylic acid may be substituted, and the substituent is an alkyl group having 1 to 6 carbon atoms (eg, methyl group, ethyl group, propyl group, isopropyl group, butyl group, s-butyl group). , T-butyl group, isobutyl group, pentyl group, hexyl group, etc.), C1-C6 alkoxy group (eg, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, s-butoxy group, t -Butoxy group, isobutyloxy group, pentyloxy group, hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), amino group, hydroxy group and the like.
レチノール又はその異性体のエステル誘導体の具体例としては、酢酸レチノール、プロピオン酸レチノール、酪酸レチノール、ピバル酸レチノール、ヘプタン酸レチノール、オクチル酸レチノール、ノナン酸レチノール、ラウリン酸レチノール、ミリスチン酸レチノール、パルミチン酸レチノール、ステアリン酸レチノール、ヘプタデカン酸レチノール、オレイン酸レチノール、リノレン酸レチノール、リノール酸レチノール、シクロペンタンカルボン酸レチノール、コハク酸レチノール、L−乳酸レチノール等やそれらの異性体が挙げられる。 Specific examples of ester derivatives of retinol or its isomers include retinol acetate, retinol propionate, retinol butyrate, retinol pivalate, retinol heptanoate, retinol octylate, retinol nonanoate, retinol laurate, retinol myristate, palmitic acid Examples thereof include retinol, retinol stearate, retinol heptadecanoate, retinol oleate, retinol linolenate, retinol linoleate, retinol cyclopentanecarboxylate, retinol succinate, L-lactic acid retinol and the isomers thereof.
レチノール又はその異性体のエーテル誘導体としては、レチノール又はその異性体のヒドロキシ基の水素原子がアルキル基、アルケニル基、アリール基、糖残基等で置換されたものが挙げられる。
アルキル基としては、炭素数1〜22のアルキル基が挙げられ、好ましくは炭素数1〜6のアルキル基である。具体例としては、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、s−ブチル基、t−ブチル基、イソブチル基、ペンチル基、ヘキシル基、ヘプチル基、オクチル基、ノニル基、デシル基、ウンデシル基、ドデシル基、トリデシル基、テトラデシル基、ペンタデシル基、ヘキサデシル基、ヘプタデシル基、オクタデシル基等が挙げられる。
アルケニル基としては、炭素数2〜12のアルケニル基が挙げられ、好ましくは炭素数2〜6のアルケニル基である。具体例としては、ビニル基、アリル基、ブテニル基(例、1−ブテニル、2−ブテニル)等が挙げられる。
これらアルキル基及びアルケニル基は置換されていても良く、その置換基としては、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、プロポキシ基、イソプロポキシ基、ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、ペンチルオキシ基、ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、ヒドロキシ基、オキソ基、フェニル基等が挙げられる。
Examples of the ether derivative of retinol or its isomer include those in which the hydrogen atom of the hydroxy group of retinol or its isomer is substituted with an alkyl group, alkenyl group, aryl group, sugar residue or the like.
As an alkyl group, a C1-C22 alkyl group is mentioned, Preferably it is a C1-C6 alkyl group. Specific examples include methyl group, ethyl group, propyl group, isopropyl group, butyl group, s-butyl group, t-butyl group, isobutyl group, pentyl group, hexyl group, heptyl group, octyl group, nonyl group, decyl group. , Undecyl group, dodecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group and the like.
Examples of the alkenyl group include alkenyl groups having 2 to 12 carbon atoms, preferably alkenyl groups having 2 to 6 carbon atoms. Specific examples include vinyl group, allyl group, butenyl group (eg, 1-butenyl, 2-butenyl) and the like.
These alkyl group and alkenyl group may be substituted, and as the substituent, an alkoxy group having 1 to 6 carbon atoms (eg, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, s-butoxy group) Group, t-butoxy group, isobutyloxy group, pentyloxy group, hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), amino group, hydroxy group, oxo group, phenyl group Etc.
アリール基としては、炭素数6〜12のアリール基が挙げられる。具体例としては、フェニル基、ナフチル基(1−ナフチル基、2−ナフチル基)等が挙げられる。また、アリール基は置換されていても良く、その置換基としては、炭素数1〜6のアルキル基(例、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、s−ブチル基、t−ブチル基、イソブチル基、ペンチル基、ヘキシル基等)、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、プロポキシ基、イソプロポキシ基、ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、ペンチルオキシ基、ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、ヒドロキシ基等が挙げられる。
糖残基としては、単糖残基、オリゴ糖残基等が挙げられる。単糖残基の具体例としては、グルコース残基、フラクトース残基、ガラクトース残基、マンノース残基、タロース残基、イドース残基、アルトロース残基、アロース残基、グロース残基、キシロース残基、リボース残基、アラビノース残基、ラムノース残基、フコース残基、グルクロン酸残基等が挙げられる。オリゴ糖残基としては、2〜10の単糖からなるオリゴ糖残基が挙げられる。オリゴ糖残基の構成単糖としては、グルコース、フラクトース、ガラクトース、マンノース、タロース、イドース、アルトロース、アロース、グロース、キシロース、リボース、アラビノース、ラムノース、フコース、グルクロン酸等が挙げられ、これらは同一又は異なっていてもよい。糖残基のヒドロキシ基の水素原子は置換されていても良く、その置換基としては、炭素数1〜7のアシル基(例、ホルミル基、アセチル基、プロピオニル基、ブチリル基、イソブチリル基、バレリル基、イソバレリル基、ピバロイル基等)、炭素数1〜6のアルキル基(例、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、s−ブチル基、t−ブチル基、イソブチル基、ペンチル基、ヘキシル基等)等が挙げられる。
Examples of the aryl group include aryl groups having 6 to 12 carbon atoms. Specific examples include a phenyl group and a naphthyl group (1-naphthyl group, 2-naphthyl group). In addition, the aryl group may be substituted, and examples of the substituent include alkyl groups having 1 to 6 carbon atoms (eg, methyl group, ethyl group, propyl group, isopropyl group, butyl group, s-butyl group, t -Butyl group, isobutyl group, pentyl group, hexyl group, etc.), C1-C6 alkoxy group (eg, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, s-butoxy group, t-butoxy group) Group, isobutyloxy group, pentyloxy group, hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), amino group, hydroxy group and the like.
Examples of sugar residues include monosaccharide residues and oligosaccharide residues. Specific examples of monosaccharide residues include glucose residues, fructose residues, galactose residues, mannose residues, talose residues, idose residues, altrose residues, allose residues, growth residues, xylose residues. , Ribose residues, arabinose residues, rhamnose residues, fucose residues, glucuronic acid residues and the like. Examples of oligosaccharide residues include oligosaccharide residues composed of 2 to 10 monosaccharides. Constituent monosaccharides of oligosaccharide residues include glucose, fructose, galactose, mannose, talose, idose, altrose, allose, growth, xylose, ribose, arabinose, rhamnose, fucose, glucuronic acid, etc., which are the same Or they may be different. The hydrogen atom of the hydroxy group of the sugar residue may be substituted. Examples of the substituent include acyl groups having 1 to 7 carbon atoms (eg, formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group). Group, isovaleryl group, pivaloyl group, etc.), alkyl group having 1 to 6 carbon atoms (eg, methyl group, ethyl group, propyl group, isopropyl group, butyl group, s-butyl group, t-butyl group, isobutyl group, pentyl) Group, hexyl group, etc.).
レチノール又はその異性体のエーテル誘導体の具体例としては、15−デオキシ−15−メトキシレチノール、15−デオキシ−15−エトキシレチノール、O−(β−D−グルコピラノシル)レチノール、O−(β−D−グルクロノピラノシル)レチノール、O−(β−D−マルトシル)レチノール等やそれらの異性体が挙げられる。 Specific examples of the ether derivative of retinol or its isomer include 15-deoxy-15-methoxyretinol, 15-deoxy-15-ethoxyretinol, O- (β-D-glucopyranosyl) retinol, O- (β-D- Glucuronopyranosyl) retinol, O- (β-D-maltosyl) retinol and the isomers thereof.
レチノイン酸又はその異性体のエステル誘導体としては、レチノイン酸と脂肪族又は芳香族アルコール、トコフェロール類等とのエステルが挙げられる。
脂肪族アルコールとしては、炭素数1〜22の脂肪族アルコールが挙げられ、好ましくは炭素数1〜18の脂肪族アルコールである。具体例としては、メタノール、エタノール、プロパノール、イソプロパノール、ブタノール、s−ブタノール、t−ブタノール、イソブタノール、ペンタノール、ヘキサノール等が挙げられる。また、脂肪族アルコールは置換されていても良く、その置換基としては、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、n−プロポキシ基、イソプロポキシ基、n−ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、n−ペンチルオキシ基、n−ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、フェニル基等が挙げられる。
芳香族アルコールとしては、炭素数6〜12の芳香族アルコールが挙げられ、具体例としては、ベンジルアルコール、1−フェニルエチルアルコール、2−フェニルエチルアルコール等が挙げられる。また、芳香族アルコールは置換されていても良く、その置換基としては、炭素数1〜6のアルキル基(例、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基、s−ブチル基、t−ブチル基、イソブチル基、n−ペンチル基、n−ヘキシル基等)、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、n−プロポキシ基、イソプロポキシ基、n−ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、n−ペンチルオキシ基、n−ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、ヒドロキシ基等が挙げられる。
トコフェロール類としては、α−トコフェロール、β−トコフェロール、δ−トコフェロール等が挙げられる。
Examples of ester derivatives of retinoic acid or its isomers include esters of retinoic acid with aliphatic or aromatic alcohols, tocopherols and the like.
Examples of the aliphatic alcohol include aliphatic alcohols having 1 to 22 carbon atoms, preferably aliphatic alcohols having 1 to 18 carbon atoms. Specific examples include methanol, ethanol, propanol, isopropanol, butanol, s-butanol, t-butanol, isobutanol, pentanol, hexanol and the like. In addition, the aliphatic alcohol may be substituted, and as the substituent, an alkoxy group having 1 to 6 carbon atoms (eg, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, s-butoxy group, t-butoxy group, isobutyloxy group, n-pentyloxy group, n-hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), amino group, phenyl Groups and the like.
Examples of the aromatic alcohol include aromatic alcohols having 6 to 12 carbon atoms, and specific examples include benzyl alcohol, 1-phenylethyl alcohol, 2-phenylethyl alcohol and the like. In addition, the aromatic alcohol may be substituted, and the substituent includes an alkyl group having 1 to 6 carbon atoms (eg, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, s -Butyl group, t-butyl group, isobutyl group, n-pentyl group, n-hexyl group, etc.), an alkoxy group having 1 to 6 carbon atoms (eg, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, s-butoxy group, t-butoxy group, isobutyloxy group, n-pentyloxy group, n-hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom) , Amino group, hydroxy group and the like.
Examples of tocopherols include α-tocopherol, β-tocopherol, and δ-tocopherol.
レチノイン酸又はその異性体のエステル誘導体の具体例としては、レチノイン酸メチル、レチノイン酸エチル、α−トコフェリルレチノエート、β−トコフェリルレチノエート、δ−トコフェリルレチノエート等やそれらの異性体が挙げられる。 Specific examples of ester derivatives of retinoic acid or its isomer include methyl retinoic acid, ethyl retinoic acid, α-tocopheryl retinoate, β-tocopheryl retinoate, δ-tocopheryl retinoate and the isomers thereof. Can be mentioned.
レチノール、レチノイン酸、レチナール又はそれらの異性体のエポキシ誘導体としては、レチノール、レチノイン酸、レチナール又はそれらの異性体の二重結合がエポキシ化されているものが挙げられ、エポキシ化の位置や数は特に限定されない。また、レチノール、レチノイン酸、レチナール又はそれらの異性体のエポキシ誘導体は、それぞれ、さらにエステル化、エーテル化されていてもよい。
具体例としては、5,6−ジヒドロ−5,6−エポキシレチノール、5,6‐エポキシ‐5,6‐ジヒドロレチノールアセテート、5,8−ジヒドロ−5,8−エポキシレチノール、11,14−エポキシ−11,14−ジヒドロレチノール、5,6;11,14−ジエポキシ−5,6,11,14−テトラヒドロレチノール、5,6−ジヒドロ−5,6−エポキシレチノイン酸等やそれらの異性体が挙げられる
Examples of epoxy derivatives of retinol, retinoic acid, retinal or their isomers include those in which the double bond of retinol, retinoic acid, retinal or their isomers is epoxidized. There is no particular limitation. Moreover, the epoxy derivatives of retinol, retinoic acid, retinal or their isomers may be further esterified and etherified, respectively.
Specific examples include 5,6-dihydro-5,6-epoxyretinol, 5,6-epoxy-5,6-dihydroretinol acetate, 5,8-dihydro-5,8-epoxyretinol, 11,14-epoxy. -11,14-dihydroretinol, 5,6; 11,14-diepoxy-5,6,11,14-tetrahydroretinol, 5,6-dihydro-5,6-epoxyretinoic acid and the isomers thereof. Be
レチノール、レチノイン酸、レチナール又はそれらの異性体の水素原子が脱離した誘導体において、脱離する水素原子の位置や数は特に限定されない。また、レチノール、レチノイン酸、レチナール又はそれらの異性体に水素原子が付加した誘導体において、付加する水素原子の位置や数は特に限定されない。また、レチノール、レチノイン酸、レチナール又はそれらの異性体の水素原子が脱離又は水素原子が付加した誘導体は、それぞれ、さらにエステル化、エーテル化されていてもよい。
具体例としては、3,4−ジデヒドロレチノール、7,8−ジデヒドロレチノール、7,8−ジデヒドロレチノールアセテート、5,6−ジヒドロレチノールアセテート、5,6−ジヒドロレチノール、3,4−ジデヒドロレチナール、5,6−ジヒドロレチナール、7,8−ジヒドロレチナール、9,10−ジヒドロレチナール、3,4−ジデヒドロレチノイン酸等やそれらの異性体が挙げられる。
In the derivative from which hydrogen atoms of retinol, retinoic acid, retinal or their isomers are eliminated, the position and number of the hydrogen atoms to be eliminated are not particularly limited. Moreover, in the derivative | guide_body which added the hydrogen atom to retinol, retinoic acid, retinal, or those isomers, the position and number of the hydrogen atom to add are not specifically limited. The derivatives of retinol, retinoic acid, retinal or their isomers from which hydrogen atoms are eliminated or hydrogen atoms are added may be further esterified or etherified, respectively.
Specific examples include 3,4-didehydroretinol, 7,8-didehydroretinol, 7,8-didehydroretinol acetate, 5,6-dihydroretinol acetate, 5,6-dihydroretinol, 3,4-di- Examples include dehydroretinal, 5,6-dihydroretinal, 7,8-dihydroretinal, 9,10-dihydroretinal, 3,4-didehydroretinoic acid, and the isomers thereof.
また、本発明のレチノール誘導体はさらに置換基を有していても良く、置換位置や置換基の数は特に限定されない。その置換基としては、炭素数1〜6のアルキル基(例、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基、s−ブチル基、t−ブチル基、イソブチル基、n−ペンチル基、n−ヘキシル基等)、炭素数1〜6のアルコキシ基(例、メトキシ基、エトキシ基、n−プロポキシ基、イソプロポキシ基、n−ブトキシ基、s−ブトキシ基、t−ブトキシ基、イソブチルオキシ基、n−ペンチルオキシ基、n−ヘキシルオキシ基等)、ハロゲン原子(例、フッ素原子、塩素原子、臭素原子、ヨウ素原子)、アミノ基、ヒドロキシ基、カルボキシ基、オキソ基等が挙げられる。 Moreover, the retinol derivative of the present invention may further have a substituent, and the substitution position and the number of substituents are not particularly limited. Examples of the substituent include alkyl groups having 1 to 6 carbon atoms (eg, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, s-butyl group, t-butyl group, isobutyl group, n -Pentyl group, n-hexyl group, etc.), C1-C6 alkoxy group (eg, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, s-butoxy group, t-butoxy group) Group, isobutyloxy group, n-pentyloxy group, n-hexyloxy group, etc.), halogen atom (eg, fluorine atom, chlorine atom, bromine atom, iodine atom), amino group, hydroxy group, carboxy group, oxo group, etc. Is mentioned.
レチノール誘導体は塩であってもよく、このような塩としては、薬理学的・生理学的に許容される塩が好ましい。具体例としては、ナトリウム塩、カリウム塩等のアルカリ金属塩;マグネシウム塩、カルシウム塩等のアルカリ土類金属塩;アンモニウム塩;モノエタノールアミン塩等のアルカノールアミン塩;等を挙げることができる。 The retinol derivative may be a salt, and as such a salt, a pharmacologically and physiologically acceptable salt is preferable. Specific examples include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; ammonium salts; alkanolamine salts such as monoethanolamine salts;
本発明では、レチノール及びその誘導体として、好ましくは、全トランスレチノール、酢酸レチノール、パルミチン酸レチノール、δ−トコフェリルレチノエートが用いられる。 In the present invention, all-trans retinol, retinol acetate, retinol palmitate, and δ-tocopheryl retinoate are preferably used as retinol and derivatives thereof.
本発明において、上記のレチノール及びその誘導体は、1種単独で使用しても、また2種以上を任意に組み合わせて混合物の状態で使用してもよい。また例えば、本発明ではレチノール及びその誘導体として、レチノールやその誘導体を含有する水産動物の組織から得た脂肪油や抽出液(ビタミンA油など)等も用いられ得る。 In this invention, said retinol and its derivative (s) may be used individually by 1 type, or may be used in the state of a mixture combining 2 or more types arbitrarily. In addition, for example, in the present invention, as retinol and derivatives thereof, fatty oils or extracts (such as vitamin A oil) obtained from tissues of marine animals containing retinol and derivatives thereof can be used.
本発明の組成物に配合するレチノール類の配合量は、本願効果を奏し得る限り特に制限されないが、通常は、組成物100gあたり0.1IU〜500万IU、より好ましくは50IU〜150万IU、さらに好ましくは300IU〜100万IU、1000IU〜50万IUのレチノール類を含むように配合される。 The amount of retinol compounded in the composition of the present invention is not particularly limited as long as the effect of the present invention can be obtained, but is usually 0.1 IU to 5 million IU, more preferably 50 IU to 1.5 million IU per 100 g of the composition. More preferably, it is blended so as to contain 300 IU to 1 million IU, 1000 IU to 500,000 IU of retinol.
ここでIUとは、当業者に通常理解され得る通り、ビタミンA類等の脂溶性ビタミン類の量に関する国際単位である。例えば、レチノールの場合1IU=約0.30μgのレチノールに対応し、酢酸レチノールの場合1IU=約0.34μgの酢酸レチノールに対応し、パルミチン酸レチノールの場合1IU=約0.55μgのパルミチン酸レチノールに対応し、δ-トコフェリルレチノエートの場合1IU=約0.72μgのδ-トコフェリルレチノエートに対応する。 Here, IU is an international unit relating to the amount of fat-soluble vitamins such as vitamin A, as can be generally understood by those skilled in the art. For example, 1 IU for retinol corresponds to about 0.30 μg of retinol, 1 IU for retinol acetate corresponds to about 0.34 μg of retinol acetate, and 1 IU for retinol palmitate to about 0.55 μg of retinol palmitate. Corresponding to 1 IU = about 0.72 μg of δ-tocopheryl retinoate in the case of δ-tocopheryl retinoate.
本発明にはさらに、ダイズタンパク質のサーモリシン分解物が用いられる〔本明細書では、これを「ダイズサーモリシン分解物」ということがある〕。 Furthermore, the thermolysin degradation product of soybean protein is used in the present invention [in this specification, this may be referred to as “soybean thermolysin degradation product”].
ダイズ(Glycin max)は、背丈約60〜70cm程度となるマメ科の一年草植物である。その種子は、枝豆などとして、あるいは豆腐や味噌、醤油などに加工されて、食用に供されることが多いことで知られる。 Soybean (Glycin max) is a leguminous annual plant with a height of about 60-70 cm. It is known that the seeds are often used as edible beans or processed into tofu, miso, soy sauce, etc.
本発明に用いられるダイズタンパク質は、かかるダイズ植物に由来する任意のタンパク質であり得るが、好ましくは、ダイズ植物の種子に由来する任意のタンパク質であり得る。 The soy protein used in the present invention can be any protein derived from such a soybean plant, but preferably can be any protein derived from the seed of a soybean plant.
本発明においては、ダイズタンパク質の供給源として、ダイズ植物そのものやダイズ植物の種子そのもの、或いは該植物や該種子の破砕物又は粉砕物等を用いてもよいが、好ましくはダイズ植物中の全成分からタンパク質成分を分離・精製したもの、より好ましくは、ダイズ植物の種子中の全成分からタンパク質成分を分離・精製したものが用いられる。このように分離・精製して得られたダイズタンパク質は、それをサーモリシンで分解して得られる産物が本願効果を奏し得る限り、ダイズ植物またはダイズ植物の種子中に含まれる実質的に全種類のタンパク質を含むものでもよいし、一部の種類のタンパク質を含むものであってもよい。 In the present invention, as a source of soybean protein, soybean plant itself, soybean plant seed itself, or a crushed or crushed product of the plant or the seed may be used. Preferably, all components in the soybean plant are used. From which the protein component is separated and purified, more preferably, the protein component is separated and purified from all the components in the seeds of soybean plants. Soy protein obtained by separating and purifying in this way can be used for substantially all kinds of soybean plant or soybean plant seeds as long as the product obtained by decomposing it with thermolysin can achieve the effect of the present application. Proteins may be included, or some types of proteins may be included.
ダイズタンパク質としては、市販品も好適に用いることができ、例えば、日清コスモフーズ(株)、ADMファーイースト(株)、昭和産業(株)、不二製油(株)、(株)光洋商会などの製造業者または供給業者から容易に入手可能である。 As the soybean protein, commercially available products can also be suitably used. For example, Nisshin Cosmo Foods Co., Ltd., ADM Far East Co., Ltd., Showa Sangyo Co., Ltd., Fuji Oil Co., Ltd., Koyo Shokai Co., Ltd. Readily available from manufacturers or suppliers.
なお本明細書において、ダイズ植物の種子とは、ダイズ種子と通常呼ばれる構造物全体を指すのみならず、例えば、脱皮ダイズ種子、脱脂ダイズ種子(粉末状のもの等)、ダイズ種子全体より得られる雪花菜(オカラ)、豆乳等でもあり得る。 In the present specification, the seeds of soybean plants not only refer to the whole structure commonly referred to as soybean seeds, but are obtained from, for example, dehulled soybean seeds, defatted soybean seeds (powdered ones, etc.) and whole soybean seeds. It can be snow flora (okara), soy milk, and the like.
本発明に用いられるサーモリシン(EC3.4.24.4)は、Bacillus thermoproteolyticusという耐熱性菌によって生産される耐熱性のプロテアーゼとして周知のものである。サーモリシンは一般に、大きな側鎖をもった疎水性のアミノ酸残基(例えば、イソロイシン、ロイシン、バリン、フェニルアラニン、メチオニン、アラニンなど)のアミノ基側のペプチド結合を切断することが知られている。 Thermolysin (EC 3.4.24.4) used in the present invention is well known as a heat-resistant protease produced by a heat-resistant bacterium called Bacillus thermoproteolyticus. Thermolysin is generally known to cleave peptide bonds on the amino group side of hydrophobic amino acid residues having large side chains (for example, isoleucine, leucine, valine, phenylalanine, methionine, alanine, etc.).
サーモリシンには、市販品も好適に用いることができ、例えば、大和化成(株)などの製造業者から容易に入手可能である。 Commercially available products can be suitably used for thermolysin, and for example, they can be easily obtained from manufacturers such as Daiwa Kasei Co., Ltd.
また本発明においては、サーモリシンと同等のペプチド切断特性(切断配列特異性など)を有するプロテアーゼとして当該分野で公知のプロテアーゼもまた、サーモリシンとして用いることができる。 In the present invention, a protease known in the art as a protease having peptide cleavage characteristics (such as cleavage sequence specificity) equivalent to thermolysin can also be used as thermolysin.
ダイズタンパク質をサーモリシンで分解する場合に用いられる反応条件は、特に制限されず、技術常識に従って当業者により適宜選択され得る。例えば、市販のサーモリシンを使用する場合には、その使用説明書に従って使用することができる。具体的な例としては、水などの溶媒に、ダイズタンパク質濃度が、一般的には0.1〜30%(w/v)、好ましくは1〜10%(w/v)程度となるようにダイズタンパク質又はダイズタンパク質を含む原料を懸濁し、この懸濁液に、一般的には0.001〜3%(w/v)、好ましくは0.01〜0.125%(w/v)程度となるようにサーモリシンを加えて分解反応を行う態様が挙げられる。一般的には、30〜80℃、好ましくは40〜70℃、より好ましくは50〜60℃の反応温度が使用され得る。また一般的には、2〜30時間、好ましくは3〜24時間、より好ましくは10〜20時間、さらに好ましくは12〜18時間の反応時間が使用され得る。反応液のpHとしては、サーモリシンの至適pH付近であることが好ましく、例えば7.0〜8.5付近であることが好ましい。 The reaction conditions used when degrading soybean protein with thermolysin are not particularly limited, and can be appropriately selected by those skilled in the art according to common general technical knowledge. For example, when using commercially available thermolysin, it can be used according to the instruction manual. As a specific example, soy protein concentration is generally 0.1 to 30% (w / v), preferably 1 to 10% (w / v) in a solvent such as water. Soy protein or a raw material containing soy protein is suspended, and this suspension is generally about 0.001 to 3% (w / v), preferably about 0.01 to 0.125% (w / v). The aspect which adds thermolysin so that it may become and performs a decomposition reaction is mentioned. In general, reaction temperatures of 30-80 ° C, preferably 40-70 ° C, more preferably 50-60 ° C may be used. In general, a reaction time of 2 to 30 hours, preferably 3 to 24 hours, more preferably 10 to 20 hours, and even more preferably 12 to 18 hours may be used. The pH of the reaction solution is preferably near the optimum pH of thermolysin, and is preferably around 7.0 to 8.5, for example.
反応の停止手段についても、特に制限はなく、公知の手段を用いることができる。かかる手段としては、例えば、加熱処理等が挙げられる。例えば、上記反応物を80〜100℃程度の温度で3〜20分間、好ましくは5〜15分間、加熱処理することにより、反応物中に含まれるサーモリシンを失活させることができる。例えば、かかる加熱処理としては、85℃で15分間の加熱処理や100℃で5分間の加熱処理などが挙げられる。 The means for stopping the reaction is not particularly limited, and known means can be used. Examples of such means include heat treatment. For example, the thermolysin contained in the reaction product can be deactivated by heat-treating the reaction product at a temperature of about 80 to 100 ° C. for 3 to 20 minutes, preferably 5 to 15 minutes. For example, examples of such heat treatment include heat treatment at 85 ° C. for 15 minutes and heat treatment at 100 ° C. for 5 minutes.
上記のような分解反応により得られるダイズサーモリシン分解物は、必要に応じて、当業者に公知の任意の方法によりさらに処理され得る。例えば、ろ過等の処理により、該分解物中の大きな固体粒子を取り除くことが好ましい。ろ過条件等は、特に制限されず、技術常識に従って当業者により適宜選択され得る。例えば、ろ紙が目詰まりを起こしやすい場合等には、ろ過助剤等も好適に用いられ得る。 The soybean thermolysin degradation product obtained by the above degradation reaction can be further processed by any method known to those skilled in the art, if necessary. For example, it is preferable to remove large solid particles in the decomposition product by a treatment such as filtration. Filtration conditions and the like are not particularly limited and may be appropriately selected by those skilled in the art according to common general technical knowledge. For example, when the filter paper is likely to be clogged, a filter aid or the like can be suitably used.
また、前記分解物を減圧濃縮し、次いで凍結乾燥することにより、粉末化することもできる。減圧濃縮および凍結乾燥の際に使用される条件や機器類は、特に制限されず、技術常識に従って当業者により適宜選択され得る。このようにして粉末化された分解物は、そのまま又は水などの溶媒に溶かして、用いることができる。 Further, the decomposition product can be pulverized by concentrating under reduced pressure and then freeze-drying. The conditions and equipment used in the concentration under reduced pressure and lyophilization are not particularly limited and can be appropriately selected by those skilled in the art according to common general technical knowledge. The decomposition product pulverized in this way can be used as it is or after being dissolved in a solvent such as water.
本発明に用いられる分解物は、ダイズタンパク質をサーモリシンで分解することにより生じた多種多様なペプチドを実質的に全て含んだ状態であってもよいし、又は、そのような多種多様なペプチドを、細胞におけるヒアルロン酸産生促進能の有無を指標として及び/又は線維芽細胞増殖促進能を指標として、公知の方法でさらに分画・精製して得られる一部分などであってもよい。しかし簡便には、ダイズタンパク質をサーモリシンで分解して得られる多種多様なペプチドを実質的に全て含んだ状態でそのまま用いる。ヒアルロン酸産生促進能の有無及び/又は線維芽細胞増殖促進能の有無は、例えば、後述の実施例等に記載のようにして確認することができる。 The degradation product used in the present invention may be in a state containing substantially all of a wide variety of peptides generated by degrading soybean protein with thermolysin, or such a wide variety of peptides, It may be a portion obtained by further fractionation and purification by a known method using the presence or absence of hyaluronic acid production promoting ability in cells and / or fibroblast proliferation promoting ability as an index. However, for convenience, the soy protein is used as it is in a state of containing substantially all of a wide variety of peptides obtained by decomposing the protein with thermolysin. The presence or absence of hyaluronic acid production promoting ability and / or the presence or absence of fibroblast proliferation promoting ability can be confirmed, for example, as described in Examples and the like described later.
なお、本明細書において用語「細胞におけるヒアルロン酸産生促進能を有する」とは、被験物を細胞に作用させた場合に、当該被験物を細胞に作用させない場合と比較して、細胞におけるヒアルロン酸の産生量が増加することを意味する。特定の態様では、当該用語における細胞とは角化細胞を意味し、さらに特定の態様では表皮角化細胞を意味する。
また、本発明において用語「線維芽細胞増殖促進能を有する」とは、被験物を線維芽細胞に作用させた場合に、当該被験物を作用させない場合と比較して、線維芽細胞の増殖が促進されることを意味する。特定の態様では、当該用語における線維芽細胞とは皮膚線維芽細胞を意味する。
In this specification, the term “having the ability to promote hyaluronic acid production in a cell” means that when a test substance is allowed to act on a cell, hyaluronic acid in the cell is compared with a case where the test substance is not allowed to act on the cell. This means that the production amount of increases. In a particular embodiment, the cell in the term means a keratinocyte, and in a particular embodiment means an epidermal keratinocyte.
Further, in the present invention, the term “having the ability to promote fibroblast proliferation” means that when a test substance is allowed to act on fibroblasts, the proliferation of fibroblasts is greater than when the test substance is not allowed to act. It means being promoted. In certain embodiments, fibroblasts in the term refer to dermal fibroblasts.
本発明に用いられるダイズタンパク質のサーモリシン分解物の平均分子量は、好ましくは300〜10000である。該平均分子量は、細胞への浸透性を高めてより高い効果を得る観点から、より好ましくは400〜5000であり、さらに好ましくは500〜3500であり、さらにより好ましくは550〜3200であり、特に好ましくは1000〜2000である。分解物の平均分子量は、当業者に公知の任意の方法により測定することができ、例えば、後述の実施例に記載のようにしてゲル浸透クロマトグラフィー(GPC)法により容易に測定することができる。 The average molecular weight of the thermolysin decomposition product of soybean protein used in the present invention is preferably 300 to 10,000. The average molecular weight is more preferably 400 to 5000, still more preferably 500 to 3500, and even more preferably 550 to 3200, from the viewpoint of increasing the permeability to cells and obtaining a higher effect. Preferably it is 1000-2000. The average molecular weight of the degradation product can be measured by any method known to those skilled in the art, and for example, it can be easily measured by gel permeation chromatography (GPC) as described in the Examples below. .
本発明の組成物に配合するダイズサーモリシン分解物の配合量は、本願効果を奏し得る限り特に制限されないが、通常は組成物全体に対して0.0001〜70重量%、より好ましくは0.001〜50重量%、さらに好ましくは0.001〜30重量%、さらにより好ましくは0.01〜20重量とするのがよい。 The blending amount of the soybean thermolysin degradation product blended in the composition of the present invention is not particularly limited as long as the effect of the present invention can be obtained, but is usually 0.0001 to 70% by weight, more preferably 0.001 based on the entire composition. ˜50 wt%, more preferably 0.001 to 30 wt%, and even more preferably 0.01 to 20 wt%.
また、本発明の組成物におけるダイズサーモリシン分解物とレチノール類との配合比は、本願効果を奏し得る限り特に制限されないが、通常は、ダイズサーモリシン分解物100μgあたり1×10−8IU〜1×108IU、好ましくは1×10−7IU〜1×106IU、より好ましくは1×10−6IU〜1×104IU、さらに好ましくは1×10−5IU〜1×103IU、特に好ましくは1×10−5IU〜1×10−4IUの範囲内とするのがよい。 Moreover, the blending ratio of the soybean thermolysin degradation product and the retinols in the composition of the present invention is not particularly limited as long as the effect of the present application can be achieved, but usually 1 × 10 −8 IU to 1 × per 100 μg of soybean thermolysin degradation product. 10 8 IU, preferably 1 × 10 −7 IU to 1 × 10 6 IU, more preferably 1 × 10 −6 IU to 1 × 10 4 IU, and even more preferably 1 × 10 −5 IU to 1 × 10 3 IU Particularly preferably, it should be in the range of 1 × 10 −5 IU to 1 × 10 −4 IU.
本発明の組成物には、前述したようなレチノール類及びダイズサーモリシン分解物に加えて、レチノール類又はダイズサーモリシン分解物の作用を増強または補足する目的で、あるいは本願組成物に他の有用な作用を付加するため、美白成分、抗炎症成分、抗菌成分、細胞賦活化成分、収斂成分、抗酸化成分、ニキビ改善成分、コラーゲン等の生体成分合成促進成分、血行促進成分、保湿成分、老化防止成分等の各種成分を1種または2種以上組み合わせて配合することができる。好ましくは美白成分、抗炎症成分、抗菌成分、細胞賦活化成分、収斂成分、抗酸化成分、老化防止成分または保湿成分の1種または2種以上の成分である。これらの各成分としては、医薬品、医薬部外品、食品または化粧品分野において使用され得るものであれば特に制限されず、任意のものを適宜選択し使用することができる。 In addition to the retinols and soybean thermolysin degradation product as described above, the composition of the present invention has the purpose of enhancing or supplementing the action of retinols or soybean thermolysin degradation product, or other useful effects on the composition of the present application. Whitening component, anti-inflammatory component, antibacterial component, cell activation component, astringent component, antioxidant component, acne improving component, biosynthesis synthesis component such as collagen, blood circulation promoting component, moisturizing component, anti-aging component Such various components can be blended in one kind or in combination of two or more kinds. Preferred are one or more of whitening components, anti-inflammatory components, antibacterial components, cell activation components, astringent components, antioxidant components, anti-aging components or moisturizing components. These components are not particularly limited as long as they can be used in the fields of pharmaceuticals, quasi drugs, foods, and cosmetics, and arbitrary components can be appropriately selected and used.
例えば、美白成分としては、プラセンタ;アルブチン;コウジ酸;エラグ酸;フィチン酸;ルシノール;カモミラET、パントテン酸又はその誘導体等のビタミン類等が挙げられる。このうち、好ましいものとしては、パントテン酸又はその誘導体、エラグ酸、フィチン酸を挙げることができる。これらの美白成分は1種または2種以上を用いてもよい。 Examples of whitening ingredients include placenta; arbutin; kojic acid; ellagic acid; phytic acid; lucinol; vitamins such as chamomile ET, pantothenic acid or derivatives thereof. Among these, as a preferable thing, pantothenic acid or its derivative (s), ellagic acid, and phytic acid can be mentioned. These whitening components may be used alone or in combination of two or more.
美白作用を有する植物成分を美白成分として用いてもよく、かかる植物成分としては、イリス(アイリス)、アーモンド、アロエ、イチョウ、ウーロン茶、エイジツ、オウゴン、オウレン、オトギリソウ、オドリコソウ、海藻、カッコン、クチナシ、クジン、クロレラ、ゴバイシ、コムギ、コメ、コメハイガ、オリザノール、コメヌカ、サイシン、サンショウ、シソ、シャクヤク、センキュウ、ソウハクヒ、ダイズ、納豆、茶、トウキ、トウキンセンカ、ニンニク、ハマメリス、ベニバナ、ボタンピ、ヨクイニン、アメジスト、アセンヤク、アセビワラビ、イヌマキ、エノキ、カキ(Diospyros kaki)、キササゲ、クロマメ、ゲンチアナ、ゲンジン、サルサ、サヤインゲン、ショクマ、ジュウロウ、セージ、ゼンコ、ダイコン、ツツジ、ツクシハギ、トシン、ニガキ、パセリ、ヒイラギ、ホップ、マルバハギ、チョウジ、カンゾウ等の植物に由来する成分が挙げられる。好ましくは、イリス(アイリス)、アロエ、イチョウ、ウーロン茶、エイジツ、オウゴン、オウレン、オトギリソウ、オドリコソウ、海藻、カッコン、クチナシ、クジン、ゴバイシ、コムギ、コメ、コメヌカ、サイシン、サンショウ、シソ、シャクヤク、センキュウ、ソウハクヒ、茶、トウキ、トウキンセンカ、ハマメリス、ベニバナ、ボタンピ、ヨクイニン、アメジスト、アセンヤク、エノキ、カキ(Diospyros kaki)、キササゲ、クロマメ、ゲンチアナ、サルサ、サヤインゲン、ジュウロウ、セージ、ゼンコ、ダイコン、ツツジ、ツクシハギ、トシン、ニガキ、パセリ、ヒイラギ、ホップ、チョウジ、カンゾウの植物由来成分であり、より好ましくは、イリス(アイリス)、アロエ、イチョウ、エイジツ、オウゴン、オウレン、オトギリソウ、クチナシ、クジン、コメ、コメヌカ、サイシン、シャクヤク、センキュウ、ソウハクヒ、茶、トウキ、トウキンセンカ、ハマメリス、ベニバナ、ボタンピ、アメジスト、アセンヤク、エノキ、カキ(Diospyros kaki)、セージ、ダイコン、ツツジ、パセリ、ホップ、カンゾウ及びヨクイニンの植物由来成分が挙げられる。これらの植物成分を本発明の組成物に用いる場合、植物成分の形態は特に制限されないが、通常は植物エキス(植物抽出物)や精油などの態様で使用することができる。なお、上記植物成分中に記載の( )内は、その植物の学名、別名または生薬名である。 Plant components having a whitening effect may be used as a whitening component, such as Iris (iris), almond, aloe, ginkgo, oolong tea, Ages, Ogon, Ouren, Hypericum persica, Adrianthus, seaweed, cuckoo, gardenia, Kujin, chlorella, gobaishi, wheat, rice, rice haiga, oryzanol, rice bran, saishin, salamander, perilla, peony, senkyu, sakuhaku, soybeans, natto, tea, toki, eucalyptus, garlic, hamamelis, safflower, buttonpi, yokuinin, Amethyst, asenyaku, acebi bracken, oyster, enoki, oyster (Diospyros kaki), cattle, black bean, gentian, genzin, salsa, sweet bean, shouma, jujuro, sage, senko, radish, azalea, azalea, Ingredients derived from plants such as Toshin, Nigaki, Parsley, Holly, Hop, Marubahagi, Clove, and Licorice. Preferably, Iris (Iris), Aloe, Ginkgo, Oolong tea, Ages, Ogon, Oulen, Hypericum, Olysam, Seaweed, Cuckoo, Gardenia, Kujin, Gobaishi, Wheat, Rice, Rice bran, Saishin, Salamander, Perilla, Peonies, Senkyu , Sakuhakuhi, Tea, Toki, Toki-Senka, Hamelis, Safflower, Buttonpi, Yokuinin, Amethyst, Asenyaku, Enoki, Oyster (Diospyros kaki), Cattle, Black Bean, Gentian, Salsa, Soyagen, Juju, Sage, Zenko, Daikon, Tsuji It is a plant-derived component of Tsukuhashigi, Toshin, Nigaki, Parsley, Holly, Hop, Clove, Licorice, and more preferably Iris (Iris), Aloe, Ginkgo, Ages, Ogon, Oulen, Hypericum, Hypericum Chinese pear, kujin, rice, rice bran, saishin, peony, senkyuu, sakuhakuhi, tea, touki, kansenka, hamamelis, safflower, buttonpi, amethyst, asenyaku, enoki, oyster (Diospyros kaki), sage, radish, azalea, parsley, parsley , Plant-derived components of licorice and yakuinin. When these plant components are used in the composition of the present invention, the form of the plant component is not particularly limited, but can usually be used in the form of a plant extract (plant extract) or an essential oil. In addition, the inside of () described in the said plant component is the scientific name of the plant, an alias, or a crude drug name.
上記美白成分を用いる場合、本願組成物に配合する割合は、好ましくは0.0003〜10重量%であり、より好ましくは0.01〜5重量%である。 When the whitening component is used, the proportion to be blended in the composition of the present application is preferably 0.0003 to 10% by weight, more preferably 0.01 to 5% by weight.
美白成分として美白作用のある植物成分を用いる場合は、目的に応じて1種もしくは2種以上を任意に組み合わせて使用することができる。上記植物成分を美白成分として用いる場合、本願組成物への配合割合は、エキスや精油などの抽出物換算で、通常0.00001〜20重量%、好ましくは0.0001〜15重量%、より好ましくは0.001〜10重量%である。 When a plant component having a whitening effect is used as the whitening component, one or two or more kinds can be used in any combination depending on the purpose. When the plant component is used as a whitening component, the blending ratio in the composition of the present application is usually 0.00001 to 20% by weight, preferably 0.0001 to 15% by weight, more preferably in terms of extracts such as extracts and essential oils. Is 0.001 to 10% by weight.
抗炎症成分としては、アラントイン、カラミン、グリチルリチン酸又はその誘導体、グリチルレチン酸又はその誘導体、酸化亜鉛、グアイアズレン、酢酸トコフェロール、塩酸ピリドキシン、メントール、カンフル、テレピン油、インドメタシン、サリチル酸又はその誘導体等が挙げられる。好ましくはアラントイン、グリチルリチン酸又はその誘導体、グリチルレチン酸又はその誘導体、グアイアズレン、メントールである。 Anti-inflammatory components include allantoin, calamine, glycyrrhizic acid or derivatives thereof, glycyrrhetinic acid or derivatives thereof, zinc oxide, guaiazulene, tocopherol acetate, pyridoxine hydrochloride, menthol, camphor, turpentine oil, indomethacin, salicylic acid or derivatives thereof. . Preferred are allantoin, glycyrrhizic acid or a derivative thereof, glycyrrhetinic acid or a derivative thereof, guaiazulene, or menthol.
上記抗炎症成分を用いる場合、本願組成物に配合する割合は、好ましくは0.0003〜10重量%であり、より好ましくは0.01〜5重量%である。 When using the said anti-inflammatory component, the ratio mix | blended with this-application composition becomes like this. Preferably it is 0.0003 to 10 weight%, More preferably, it is 0.01 to 5 weight%.
抗菌成分としては、クロルヘキシジン、サリチル酸、塩化ベンザルコニウム、アクリノール、エタノール、塩化ベンゼトニウム、クレゾール、グルコン酸及びその誘導体、ポピドンヨード、ヨウ化カリウム、ヨウ素、イソプロピルメチルフェノール、トリクロカルバン、トリクロサン、感光素101号、感光素201号、パラベン、フェノキシエタノール、1,2-ペンタンジオール、塩酸アルキルジアミノグリシン等が挙げられる。好ましくは、塩化ベンザルコニウム、塩化ベンゼトニウム、グルコン酸及びその誘導体、イソプロピルメチルフェノール、トリクロカルバン、トリクロサン、感光素101号、感光素201号、パラベン、フェノキシエタノール、1,2-ペンタンジオール、塩酸アルキルジアミノグリシン等が挙げられる。さらに好ましくは、塩化ベンザルコニウム、グルコン酸及びその誘導体、塩化ベンゼトニウム、イソプロピルメチルフェノールである。 Antibacterial components include chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, ethanol, benzethonium chloride, cresol, gluconic acid and derivatives thereof, popidone iodine, potassium iodide, iodine, isopropylmethylphenol, triclocarban, triclosan, photosensitizer 101 Photosensitive element 201, paraben, phenoxyethanol, 1,2-pentanediol, alkyldiaminoglycine hydrochloride and the like. Preferably, benzalkonium chloride, benzethonium chloride, gluconic acid and derivatives thereof, isopropylmethylphenol, triclocarban, triclosan, photosensitizer 101, photosensitizer 201, paraben, phenoxyethanol, 1,2-pentanediol, alkyldiamino hydrochloride Examples include glycine. More preferred are benzalkonium chloride, gluconic acid and its derivatives, benzethonium chloride, and isopropylmethylphenol.
上記抗菌成分を用いる場合、本願組成物に配合する割合は、好ましくは0.0003〜10重量%であり、より好ましくは0.01〜5重量%である。 When using the said antibacterial component, the ratio mix | blended with this-application composition becomes like this. Preferably it is 0.0003 to 10 weight%, More preferably, it is 0.01 to 5 weight%.
細胞賦活化成分としては、γ-アミノ酪酸、ε-アミノカプロン酸などのアミノ酸類:チアミン、リボフラビン、塩酸ピリドキシン、パントテン酸類などのビタミン類:グリコール酸、乳酸などのα-ヒドロキシ酸類:タンニン、フラボノイド、サポニン、アラントイン、感光素301号などが挙げられる。好ましくは、γ-アミノ酪酸、ε-アミノカプロン酸などのアミノ酸類:チアミン、リボフラビン、塩酸ピリドキシン、パントテン酸類などのビタミン類である。 Cell activation components include amino acids such as γ-aminobutyric acid and ε-aminocaproic acid: thiamine, riboflavin, pyridoxine hydrochloride, pantothenic acids and other vitamins: glycolic acid, α-hydroxy acids such as lactic acid: tannin, flavonoids, Examples include saponin, allantoin, and photosensitive element 301. Preferred are amino acids such as γ-aminobutyric acid and ε-aminocaproic acid: vitamins such as thiamine, riboflavin, pyridoxine hydrochloride and pantothenic acids.
上記細胞賦活化成分を用いる場合、本願組成物に配合する割合は、好ましくは0.0003〜10重量%であり、より好ましくは0.01〜5重量%である。 When using the said cell activation component, the ratio mix | blended with this-application composition becomes like this. Preferably it is 0.0003 to 10 weight%, More preferably, it is 0.01 to 5 weight%.
収斂成分としては、ミョウバン、クロロヒドロキシアルミニウム、塩化アルミニウム、アラントインアルミニウム塩、硫酸亜鉛、硫酸アルミニウムカリウム等の金属塩;タンニン酸、クエン酸、乳酸、コハク酸などの有機酸を挙げることができる。好ましくは、ミョウバン、クロロヒドロキシアルミニウム、塩化アルミニウム、アラントインアルミニウム塩、硫酸アルミニウムカリウム、タンニン酸である。 Examples of the astringent component include metal salts such as alum, chlorohydroxyaluminum, aluminum chloride, allantoin aluminum salt, zinc sulfate, and aluminum potassium sulfate; organic acids such as tannic acid, citric acid, lactic acid, and succinic acid. Alum, chlorohydroxyaluminum, aluminum chloride, allantoin aluminum salt, aluminum potassium sulfate, and tannic acid are preferred.
収斂成分を用いる場合、本願組成物に配合する割合は、通常0.0003〜10重量%、好ましくは0.01〜5重量%、より好ましくは0.01〜5重量%である。 When the astringent component is used, the ratio of the composition of the present application is usually 0.0003 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.01 to 5% by weight.
抗酸化成分としては、ブチルヒドロキシアニソール、ジブチルヒドロキシトルエン、亜硫酸水素ナトリウム、エリソルビン酸及びその塩、フラボノイド、グルタチオン、グルタチオンペルオキシダーゼ、グルタチオン-S-トランスフェラーゼ、カタラーゼ、スーパーオキサイドジスムターゼ、チオレドキシン、タウリン、チオタウリン、ヒポタウリンなどが挙げられる。好ましくは、チオタウリン、ヒポタウリン、チオレドキシン、フラボノイドである。 Antioxidant components include butylhydroxyanisole, dibutylhydroxytoluene, sodium bisulfite, erythorbic acid and its salts, flavonoids, glutathione, glutathione peroxidase, glutathione-S-transferase, catalase, superoxide dismutase, thioredoxin, taurine, thiotaurine, hypotaurine Etc. Preferred are thiotaurine, hypotaurine, thioredoxin, and flavonoid.
抗酸化成分を用いる場合、本願組成物に配合する割合は、通常0.00001〜10重量%、好ましくは0.0001〜5重量%、より好ましくは0.001〜5重量%である。 When using an antioxidant component, the proportion of the composition of the present application is usually 0.0001 to 10% by weight, preferably 0.0001 to 5% by weight, and more preferably 0.001 to 5% by weight.
老化防止成分としては、パンガミン酸、カイネチン、ウルソール酸、ウコンエキス、スフィンゴシン誘導体、ケイ素、ケイ酸、N−メチル−L−セリン、メバロノラクトン等が挙げられる。好ましくは、カイネチンである。 Examples of the anti-aging component include pangamic acid, kinetin, ursolic acid, turmeric extract, sphingosine derivative, silicon, silicic acid, N-methyl-L-serine, and mevalonolactone. Preferably, it is kinetin.
上記老化防止成分を用いる場合、本願組成物に配合する割合は、好ましくは0.0003〜10重量%であり、より好ましくは0.01〜5重量%である。 When using the said anti-aging component, the ratio mix | blended with this-application composition becomes like this. Preferably it is 0.0003 to 10 weight%, More preferably, it is 0.01 to 5 weight%.
保湿成分としては、アラニン、セリン、ロイシン、イソロイシン、スレオニン、グリシン、プロリン、ヒドロキシプロリン、グルコサミン、テアニンなどのアミノ酸及びその誘導体;グリセリン、1,3-ブチレングリコール、プロピレングリコール、ポリエチレングリコールなどの多価アルコール;ソルビトールなどの糖アルコール;レシチン、水素添加レシチン等のリン脂質;ヒアルロン酸プロピレングリコール、ヘパリン、コンドロイチン等のムコ多糖;乳酸、ピロリドンカルボン酸ナトリウム、尿素などのNMF由来成分等が挙げられる。好ましいものは、アラニン、セリン、グリシン、プロリン、ヒドロキシプロリン、グルコサミン、テアニン、コラーゲン、コラーゲンペプチド、グリセリン、1,3-ブチレングリコール、水素添加レシチン、ヒアルロン酸プロピレングリコール、ヘパリン、コンドロイチン、乳酸、ピロリドンカルボン酸ナトリウムである。 As moisturizing ingredients, amino acids such as alanine, serine, leucine, isoleucine, threonine, glycine, proline, hydroxyproline, glucosamine, theanine and derivatives thereof; polyvalent such as glycerin, 1,3-butylene glycol, propylene glycol, polyethylene glycol, etc. Examples include alcohols; sugar alcohols such as sorbitol; phospholipids such as lecithin and hydrogenated lecithin; mucopolysaccharides such as propylene glycol hyaluronate, heparin and chondroitin; and NMF-derived components such as lactic acid, sodium pyrrolidonecarboxylate, and urea. Preferred are alanine, serine, glycine, proline, hydroxyproline, glucosamine, theanine, collagen, collagen peptide, glycerin, 1,3-butylene glycol, hydrogenated lecithin, propylene glycol hyaluronate, heparin, chondroitin, lactic acid, pyrrolidone carboxylic acid Sodium acid.
保湿成分を用いる場合、本願組成物に配合する割合としては、通常0.1〜10重量%、好ましくは0.5〜7.5重量%、より好ましくは0.5〜5重量%を挙げることができる。 When using a moisturizing component, the proportion to be blended in the composition of the present application is usually 0.1 to 10% by weight, preferably 0.5 to 7.5% by weight, more preferably 0.5 to 5% by weight. Can do.
本発明の組成物は、上記各成分に加えて組成物の用途あるいは剤形に応じて、医薬品、医薬部外品、化粧品または食品の分野に通常使用される成分を適宜配合しても良い。配合できる成分としては、特に制限されないが、例えば、アミノ酸類、アルコール類、多価アルコール類、糖類、ガム質、多糖類などの高分子化合物、界面活性剤、可溶化成分、油脂類、経皮吸収促進成分、防腐・抗菌・殺菌剤、pH調整剤、キレート剤、抗酸化剤、酵素成分、結合剤、崩壊剤、滑沢剤、流動化剤、清涼化剤の他、ミネラル類、細胞賦活剤、滋養強壮剤、賦形剤、増粘剤、安定化剤、保存剤、等張化剤、分散剤、吸着剤、崩壊補助剤、湿潤剤または湿潤調節剤、防湿剤、着色料、着香剤または香料、芳香剤、還元剤、可溶化剤、溶解補助剤、発泡剤、粘稠剤または粘稠化剤、溶剤、基剤、乳化剤、可塑剤、緩衝剤、光沢化剤などをあげることができる。特に界面活性剤、可溶化成分または油脂類を配合することによって、製剤中におけるレチノール類の安定性を高めることができ、また外用組成物とする場合にはその製剤の使用感をより向上させることができる。また発明の組成物が外用組成物である場合には、さらに経皮吸収促進成分を配合するのが好ましい。 In addition to the above components, the composition of the present invention may be appropriately mixed with components usually used in the field of pharmaceuticals, quasi drugs, cosmetics or foods, depending on the use or dosage form of the composition. The component that can be blended is not particularly limited, but for example, amino acids, alcohols, polyhydric alcohols, saccharides, gums, polysaccharides and other high molecular compounds, surfactants, solubilizing components, fats and oils, transdermal Absorption-promoting ingredients, antiseptic / antibacterial / bactericidal agents, pH adjusters, chelating agents, antioxidants, enzyme components, binders, disintegrating agents, lubricants, fluidizing agents, cooling agents, minerals, cell activation Agents, nourishing tonics, excipients, thickeners, stabilizers, preservatives, isotonic agents, dispersants, adsorbents, disintegration aids, wetting agents or wetting regulators, dampening agents, coloring agents, wearing Perfume or fragrance, fragrance, reducing agent, solubilizer, solubilizer, foaming agent, thickener or thickener, solvent, base, emulsifier, plasticizer, buffer, brightener, etc. be able to. In particular, by adding a surfactant, a solubilizing component or fats and oils, the stability of retinols in the preparation can be increased, and when the composition is for external use, the usability of the preparation should be further improved. Can do. When the composition of the invention is an external composition, it is preferable to further blend a transdermal absorption promoting component.
ここで用いられる界面活性剤としては、ポリオキシエチレン(以下、POEという)−オクチルドデシルアルコールやPOE−2−デシルテトラデシルアルコール等のPOE−分岐アルキルエーテル;POE −オレイルアルコールエーテルやPOE−セチルアルコールエーテル等のPOE−アルキルエーテル;ソルビタンモノオレエート、ソルビタンモノイソステアレート及びソルビタンモノラウレート等のソルビタンエステル;POE−ソルビタンモノオレエート、POE−ソルビタンモノイソステアレート、及びPOE−ソルビタンモノラウレート等のPOE−ソルビタンエステル;グリセリンモノオレエート、グリセリンモノステアレート、及びグリセリンモノミリステート等のグリセリン脂肪酸エステル;POE−グリセリンモノオレエート、POE−グリセリンモノステアレート、及びPOE−グリセリンモノミリステート等のPOE−グリセリン脂肪酸エステル;POE−ジヒドロコレステロールエステル、POE−硬化ヒマシ油、及びPOE−硬化ヒマシ油イソステアレート等のPOE−硬化ヒマシ油脂肪酸エステル;POE−オクチルフェニルエーテル等のPOE−アルキルアリールエーテル;モノイソステアリルグリセリルエーテルやモノミリスチルグリセリルエーテル等のグリセリンアルキルエーテル;POE−モノステアリルグリセリルエーテル、POE−モノミリスチルグリセリルエーテル等のPOE−グリセリンアルキルエーテル;ジグリセリルモノステアレート、デカグリセリルデカステアレート、デカグリセリルデカイソステアレート、及びジグリセリルジイソステアレート等のポリグリセリン脂肪酸エステル、等の各種非イオン界面活性剤:あるいはレシチン、水素添加レシチン、サポニン、サーファクチンナトリウム、コレステロール、胆汁酸などの天然由来の界面活性剤等を例示することができる。これらの界面活性剤は、1種単独で使用してもまた2種以上を任意に組み合わせて使用してもよい。 Examples of the surfactant used herein include POE-branched alkyl ethers such as polyoxyethylene (hereinafter referred to as POE) -octyldodecyl alcohol and POE-2-decyltetradecyl alcohol; POE-oleyl alcohol ether and POE-cetyl alcohol. POE-alkyl ethers such as ethers; sorbitan esters such as sorbitan monooleate, sorbitan monoisostearate and sorbitan monolaurate; POE-sorbitan monooleate, POE-sorbitan monoisostearate, and POE-sorbitan monolaurate POE-sorbitan esters such as glycerol; glycerol fatty acid esters such as glycerol monooleate, glycerol monostearate, and glycerol monomyristate; POE-glycerol monoo POE-cured fatty acid esters such as reate, POE-glycerin monostearate, and POE-glycerin monomyristate; POE-cured such as POE-dihydrocholesterol ester, POE-cured castor oil, and POE-cured castor oil isostearate Castor oil fatty acid ester; POE-alkyl aryl ethers such as POE-octylphenyl ether; Glycerin alkyl ethers such as monoisostearyl glyceryl ether and monomyristyl glyceryl ether; POE such as POE-monostearyl glyceryl ether and POE-monomyristyl glyceryl ether -Glycerin alkyl ethers; diglyceryl monostearate, decaglyceryl decastearate, decaglyceryl decaisostearate, and diglyceride Various nonionic surfactants such as polyglycerin fatty acid esters such as rildiisostearate: or naturally derived surfactants such as lecithin, hydrogenated lecithin, saponin, surfactin sodium, cholesterol, bile acids, etc. be able to. These surfactants may be used alone or in any combination of two or more.
界面活性剤を使用する場合、本願組成物への配合割合としては、本発明の効果を妨げないことを限度として特に制限されず、通常は本願組成物中に0.01〜30重量%の割合で含まれるような範囲で適宜選択して使用することができる。本願組成物中の有効成分の安定性等の観点からは、好ましくは0.1〜20重量%、より好ましくは0.5〜10重量%の範囲を挙げることができる。 When a surfactant is used, the blending ratio in the composition of the present application is not particularly limited as long as it does not interfere with the effects of the present invention, and usually 0.01 to 30% by weight in the composition of the present application. Can be appropriately selected and used within the range included in the above. From the viewpoint of the stability of the active ingredient in the composition of the present application, it is preferably 0.1 to 20% by weight, more preferably 0.5 to 10% by weight.
可溶化成分としては、例えば、エタノール等の低級アルコール、グリセリン,エチレングリコール等の多価アルコール、水素添加大豆リン脂質、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンラノリンアルコール、ポリオキシエチレンヒマシ油、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンステロール、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンポリオキシプロピレンアルキルエーテル、ポリオキシエチレンアルキルフェニルエーテル等を挙げることができる。好ましくは、エタノール、グリセリン、エチレングリコール、ジエチレングリコール、ジプロピレングリコール、水素添加大豆リン脂質、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンラノリンアルコール、ポリオキシエチレンヒマシ油、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンアルキルエーテルであり、より好ましくは、エタノール、グリセリン、エチレングリコール、ジエチレングリコール、ジプロピレングリコール、水素添加大豆リン脂質である。これらの可溶化成分は、1種単独で使用しても、または2種以上を任意に組み合わせて用いてもよい。 Examples of solubilizing components include lower alcohols such as ethanol, polyhydric alcohols such as glycerin and ethylene glycol, hydrogenated soybean phospholipid, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene lanolin alcohol, polyoxyethylene castor oil, poly Examples thereof include oxyethylene hydrogenated castor oil, polyoxyethylene sterol, polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkylphenyl ether, and the like. Preferably, ethanol, glycerin, ethylene glycol, diethylene glycol, dipropylene glycol, hydrogenated soybean phospholipid, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene lanolin alcohol, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxy Ethylene alkyl ether, more preferably ethanol, glycerin, ethylene glycol, diethylene glycol, dipropylene glycol, and hydrogenated soybean phospholipid. These solubilizing components may be used alone or in any combination of two or more.
これらの可溶化成分を使用する場合、本願組成物への配合割合としては、本発明の効果を妨げないことを限度として特に制限されず、通常は本願組成物中に0.01〜70重量%の割合で含まれるような範囲で適宜選択して使用することができる。本願成物中の有効成分の安定性等の観点からは、好ましくは0.1〜50重量%、より好ましくは0.1〜30重量%の範囲を挙げることができる。 When using these solubilizing components, the blending ratio in the composition of the present application is not particularly limited as long as it does not interfere with the effects of the present invention, and usually 0.01 to 70% by weight in the composition of the present application. Can be appropriately selected and used within such a range that is included in the ratio. From the viewpoint of the stability of the active ingredient in the present application composition, it is preferably 0.1 to 50% by weight, more preferably 0.1 to 30% by weight.
油脂類としては、例えば、中鎖脂肪酸トリグリセリド等の合成油脂;大豆油、米油、菜種油、綿実油、ゴマ油、サフラワー油、ヒマシ油、オリーブ油、カカオ油、椿油、ヒマワリ油、パーム油、アマ油、シソ油、シア油、サル油、ヤシ油、木ロウ、ホホバ油、グレープシード油、及びアボガド油等の植物油脂;ミンク油、卵黄油、牛脂、乳脂、及び豚脂等の動物油脂;ミツロウ、鯨ロウ、ラノリン、カルナウバロウ、キャンデリラロウ等のロウ類;流動パラフィン、スクワレン、スクワラン、マイクロクリスタリンワックス、セレシンワックス、パラフィンワックス、ワセリン等の炭化水素類;ラウリン酸、ミリスチン酸、ステアリン酸、オレイン酸、イソステアリン酸、ベヘニン酸等の天然及び合成脂肪酸;セタノール、ステアリルアルコール、ヘキシルデカノール、オクチルデカノール、ラウリルアルコール等の天然及び合成高級アルコール;ミリスチン酸イソプロピル、パルミチン酸イソプロピル、ミリスチン酸オクチルドデシル、オレイン酸オクチルドデシル、コレステロールオレート等のエステルやエーテル類;シリコーン油等が挙げられる。これらの油脂類は、1種単独で使用しても、または2種以上を任意に組み合わせて用いてもよい。 Examples of fats and oils include synthetic fats and oils such as medium-chain fatty acid triglycerides; soybean oil, rice oil, rapeseed oil, cottonseed oil, sesame oil, safflower oil, castor oil, olive oil, cacao oil, coconut oil, sunflower oil, palm oil, flax oil Vegetable oil such as perilla oil, perilla oil, shea oil, monkey oil, palm oil, tree wax, jojoba oil, grape seed oil, and avocado oil; animal fat such as mink oil, egg yolk oil, beef tallow, milk fat, and pork fat; beeswax Waxes such as whale wax, lanolin, carnauba wax, candelilla wax; hydrocarbons such as liquid paraffin, squalene, squalane, microcrystalline wax, ceresin wax, paraffin wax, petrolatum; lauric acid, myristic acid, stearic acid, olein Natural and synthetic fatty acids such as acids, isostearic acid and behenic acid; cetanol, stearyl alcohol Natural and synthetic higher alcohols such as ru, hexyl decanol, octyl decanol, lauryl alcohol; esters and ethers such as isopropyl myristate, isopropyl palmitate, octyldodecyl myristate, octyldodecyl oleate, cholesterol oleate; silicone oil, etc. It is done. These fats and oils may be used alone or in any combination of two or more.
これらの油脂類を使用する場合、本願組成物への配合割合としては、本発明の効果を妨げないことを限度として特に制限されず、通常は本願組成物中に0.01〜70重量%の割合で含まれるような範囲で適宜選択して使用することができる。本願組成物中の有効成分の安定性等の観点からは、好ましくは0.1〜60重量%、より好ましくは0.1〜50重量%の範囲を挙げることができる。 When these fats and oils are used, the blending ratio in the composition of the present application is not particularly limited as long as the effect of the present invention is not hindered, and usually 0.01 to 70% by weight in the composition of the present application. It can be appropriately selected and used within a range that is included in a proportion. From the viewpoint of the stability of the active ingredient in the composition of the present application, the range is preferably 0.1 to 60% by weight, more preferably 0.1 to 50% by weight.
本発明の組成物は、その用途に応じて、医薬品、医薬部外品、化粧品又は食品に通常使用される剤形をとることができ、通常、固形剤、半固形剤または液剤である。具体的には、錠剤(口腔内速崩壊錠、咀嚼可能錠、発泡錠、トローチ剤、ゼリー状ドロップ剤などを含む)、丸剤、顆粒剤、細粒剤、散剤、硬カプセル剤、軟カプセル剤、ドライシロップ剤、液剤(ドリンク剤、懸濁剤、シロップ剤を含む)、ゲル剤、リポソーム剤、エキス剤、チンキ剤、レモネード剤、軟膏剤、ゼリー剤などの公知の形態をとることができる。また、必要に応じてその他の溶媒や通常使用される基剤等を配合することによって、ペースト状、ムース状、ジェル状、液状、乳液状、クリーム状、シート状(基材担持)、エアゾール状、スプレー状などの各種所望の形態に調製することができる。 The composition of the present invention can take a dosage form usually used for pharmaceuticals, quasi drugs, cosmetics or foods, and is usually a solid, semi-solid or liquid. Specifically, tablets (including orally disintegrating tablets, chewable tablets, effervescent tablets, troches, jelly drops, etc.), pills, granules, fine granules, powders, hard capsules, soft capsules , Dry syrups, liquids (including drinks, suspensions, syrups), gels, liposomes, extracts, tinctures, lemonades, ointments, jellys, etc. . In addition, pastes, mousses, gels, liquids, emulsions, creams, sheets (substrate support), aerosols can be added by blending other solvents and commonly used bases as necessary. It can be prepared in various desired forms such as spray.
これらの剤形は当該分野の通常の方法にて製造することができる。例えば、半固形剤であれば、上述のようなレチノール類とダイズサーモリシン分解物に加えて必要に応じて上記各任意成分を配合混合し、さらに必要に応じてその他の溶媒や通常使用される外用組成物の基剤等を配合することによって、ペースト状、ムース状、ジェル状、液状、乳液状、クリーム状、シート状(基材担持)、エアゾール状、スプレー状などの各種所望の形態に調製することができる。 These dosage forms can be produced by conventional methods in the art. For example, in the case of a semi-solid agent, in addition to the retinols and soybean thermolysin decomposition product as described above, the above-mentioned optional components are blended and mixed as necessary, and other solvents and commonly used externally used as necessary. Prepared in various desired forms such as paste, mousse, gel, liquid, emulsion, cream, sheet (substrate support), aerosol, spray, etc. by blending composition base can do.
本発明の組成物は、本発明の効果を奏すれば特に限定されないが、例えば医薬品、医薬部外品、食品[菓子、健康食品、栄養補助食品(バランス栄養食、サプリメントなど)を含む)、栄養機能食品、特定保健用食品を含む]などとすることができ、また化粧品ではファンデーション、口紅、マスカラ、アイシャドウ、アイライナー、眉墨及び美爪料等のメーキャップ化粧料;乳液、クリーム、ローション、オイル及びパックなどの基礎化粧料;洗顔料やクレンジング、ボディ洗浄料などの洗浄料、入浴剤などとすることができる。 The composition of the present invention is not particularly limited as long as the effects of the present invention are achieved. For example, pharmaceuticals, quasi-drugs, foods (including confectionery, health foods, nutritional supplements (balance nutritional foods, supplements, etc.)), Including nutritional functional foods and foods for specified health use, etc., and in cosmetics, makeup cosmetics such as foundations, lipsticks, mascaras, eye shadows, eyeliners, eyebrows and beauty nails; emulsions, creams, lotions, Basic cosmetics such as oils and packs; cleansing agents such as facial cleansers, cleansing and body cleaning agents, bathing agents, and the like.
本発明の組成物は内服用組成物としても外用組成物としても好適に用いられ得る。 The composition of the present invention can be suitably used as an internal composition or an external composition.
本発明の組成物は顕著なヒアルロン酸産生促進能を有するので、細胞におけるヒアルロン酸産生を促進するために好適に使用され得る。例えば、本発明の組成物は、ヒアルロン酸の減少や変性などに伴う各種障害(リューマチ,関節炎,変形性関節炎,骨関節炎などの関節障害、炎症性障害等)の治療又は予防用組成物、ヒアルロン酸の減少や変性などに起因する美容上の問題を予防又は治療するための組成物(例えば、紫外線曝露や加齢等によるヒアルロン酸の減少や変性などに起因する皮膚のシワもしくはタルミの予防および/または改善のための組成物、ヒアルロン酸の減少や変性などに起因する皮膚の弾力性もしくはハリの低下に対する予防および/または改善のための組成物等)等として好適に用いることができる。 Since the composition of the present invention has a remarkable ability to promote hyaluronic acid production, it can be suitably used to promote hyaluronic acid production in cells. For example, the composition of the present invention is a composition for treating or preventing various disorders (rheumatoid, arthritis, osteoarthritis, joint disorders such as osteoarthritis, inflammatory disorders, etc.) associated with reduction or degeneration of hyaluronic acid, hyaluronic acid A composition for preventing or treating cosmetic problems caused by acid reduction or denaturation (for example, prevention of skin wrinkles or tarmi caused by reduction or modification of hyaluronic acid due to UV exposure, aging, etc.) And / or a composition for improvement, a composition for preventing and / or improving the skin elasticity or elasticity due to reduction or modification of hyaluronic acid, and the like.
また本発明の組成物は、線維芽細胞増殖促進能を有するので、例えば、線維芽細胞の減少や不活性化などに伴う美容上の問題を予防又は治療するための組成物(例えば、紫外線曝露や加齢等による線維芽細胞の減少や不活性化などに起因する皮膚のシワもしくはタルミの予防および/または改善のための組成物、或いは線維芽細胞の減少や不活性化などに起因する皮膚の弾力性もしくはハリの低下に対する予防および/または改善のための組成物等)等として好適に用いることができる。 In addition, since the composition of the present invention has the ability to promote proliferation of fibroblasts, for example, a composition for preventing or treating cosmetic problems associated with, for example, reduction or inactivation of fibroblasts (for example, exposure to ultraviolet rays) Composition for prevention and / or improvement of skin wrinkles or tarmi caused by decrease or inactivation of fibroblasts due to aging or aging, etc., or skin caused by reduction or inactivation of fibroblasts The composition can be suitably used as a composition for preventing and / or improving the decrease in elasticity or elasticity.
以下に、実施例に基づいて本発明を詳細に説明するが、本発明はこれらの実施例によって限定されるものではない。 EXAMPLES The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.
実施例1
ダイズタンパク質のサーモリシン分解物の調製
粉末状分離ダイズタンパク質(製品名「PR-800」、不二製油株式会社製)50gを2Lの蒸留水に分散し、0.1N NaOHでpH8.0に調整した。500mgのサーモリシン(EC3.4.24.4、Bacillus thermoproteolyticus由来、製品名「サモアーゼPC10F」、大和化成株式会社製、100 units/mg)を添加して、60℃で15時間での分解を行なった。反応後、100℃で10分間煮沸してサーモリシンを失活させた。放冷後、25gのろ過助剤(ラジオライト500、昭和化学工業株式会社)を添加し、撹拌した後、ろ過を行なった。得られたろ液を500mlまで減圧濃縮し、その後凍結乾燥をして、最終的に約26gのダイズタンパク質サーモリシン分解物を得た。
Example 1
Preparation of Thermolysin Degradation Product of Soy Protein 50 g of powdered separated soy protein (product name “PR-800”, manufactured by Fuji Oil Co., Ltd.) was dispersed in 2 L of distilled water and adjusted to pH 8.0 with 0.1 N NaOH. 500 mg of thermolysin (EC3.4.24.4, derived from Bacillus thermoproteolyticus, product name “Samorose PC10F”, manufactured by Daiwa Kasei Co., Ltd., 100 units / mg) was added, and degradation was performed at 60 ° C. for 15 hours. After the reaction, the thermolysin was inactivated by boiling at 100 ° C. for 10 minutes. After allowing to cool, 25 g of filter aid (Radiolite 500, Showa Chemical Industry Co., Ltd.) was added and stirred, followed by filtration. The obtained filtrate was concentrated under reduced pressure to 500 ml, and then freeze-dried to finally obtain about 26 g of a soybean protein thermolysin degradation product.
このようにして得られた分解物の平均分子量をGPC法により測定した。凍結乾燥後のダイズサーモリシン分解物100mgを、0.1Mリン酸ナトリウム緩衝液(pH7.0)2.0ml中に溶解し、被験溶液とした。Sephadex G25(Mediumタイプ、Amersham Biosciences社製)を充填したカラム(φ2.6×100cm)を、同じ0.1Mリン酸ナトリウム緩衝液(pH7.0)で平衡化した。このカラムに被験溶液を2.0ml負荷して、流速1.0ml/分で溶出した。分子量既知のペプチド標品として、Insulin(ウシ膵臓由来、シグマ社製、分子量5733)、Insulin A chain(ウシ膵臓由来、シグマ社製、分子量2532)、およびBradykinin(シグマ社製、分子量1050)を用いた。214nmでペプチドを検出し、溶出時間から分子量分布および平均分子量を推定した。その結果、上記方法により得られたダイズサーモリシン分解物の平均分子量は、約1500であることが推定された。 The average molecular weight of the decomposition product thus obtained was measured by the GPC method. 100 mg of soybean thermolysin degradation product after lyophilization was dissolved in 2.0 ml of 0.1 M sodium phosphate buffer (pH 7.0) to prepare a test solution. A column (φ2.6 × 100 cm) packed with Sephadex G25 (Medium type, manufactured by Amersham Biosciences) was equilibrated with the same 0.1 M sodium phosphate buffer (pH 7.0). The column was loaded with 2.0 ml of the test solution and eluted at a flow rate of 1.0 ml / min. Insulin (bovine pancreas origin, Sigma, molecular weight 5733), Insulin A chain (bovine pancreas origin, Sigma, molecular weight 2532), and Bradykinin (Sigma, molecular weight 1050) are used as peptide preparations with known molecular weights. It was. Peptides were detected at 214 nm, and the molecular weight distribution and average molecular weight were estimated from the elution time. As a result, the average molecular weight of the soybean thermolysin degradation product obtained by the above method was estimated to be about 1500.
実施例2
表皮角化細胞におけるヒアルロン酸産生検定
ヒト正常表皮角化細胞(NHEK/B−3、倉敷紡績株式会社製)を48ウェルカルチャープレート中で培養した。より詳細には、0.8×104細胞/ウェルの密度でプレートに播種し、37℃で、5%炭酸ガスおよび95%空気の環境下で4日間培養を行なった。培養液は、HuMedia KG−2(倉敷紡績株式会社製)を各ウェル400μLずつ使用した。その後、培養液を除去して、下記の表1に示す被験薬を溶解した400μLの培地に交換して培養した。一方、レチノールもダイズサーモリシン分解物も添加しない培地を400μL添加したものをコントロールとして用いた。2日間培養した後、培養液を採取し、培養液中に分泌されたヒアルロン酸濃度を、酵素結合免疫測定法(ヒアルロン酸測定キット;生化学工業株式会社製)で定量した。定量結果をもとにコントロール培養液中のヒアルロン酸量を100%として、各被験培養液中のヒアルロン酸量を算出した。この結果を表1に纏める。
Example 2
Hyaluronic acid production assay in epidermal keratinocytes Human normal epidermal keratinocytes (NHEK / B-3, Kurashiki Boseki Co., Ltd.) were cultured in 48-well culture plates. More specifically, the cells were seeded at a density of 0.8 × 10 4 cells / well and cultured at 37 ° C. in an environment of 5% carbon dioxide gas and 95% air for 4 days. As a culture solution, HuMedia KG-2 (manufactured by Kurashiki Boseki Co., Ltd.) was used in an amount of 400 μL per well. Thereafter, the culture solution was removed, and the medium was replaced with a 400 μL medium in which the test drug shown in Table 1 below was dissolved, and cultured. On the other hand, a medium supplemented with 400 μL of neither retinol nor soybean thermolysin degradation product was used as a control. After culturing for 2 days, the culture solution was collected, and the hyaluronic acid concentration secreted in the culture solution was quantified by an enzyme-linked immunoassay (hyaluronic acid measurement kit; manufactured by Seikagaku Corporation). Based on the quantification results, the amount of hyaluronic acid in each test culture was calculated with the amount of hyaluronic acid in the control culture as 100%. The results are summarized in Table 1.
この結果から、レチノールとダイズサーモリシン分解物とを併用した培養液で培養した細胞では、レチノール単独の培養液で培養した場合よりもヒアルロン酸産生量が顕著に増加し、ダイズタンパク質をサーモリシンという特定のプロテアーゼで処理することにより得られる分解物がレチノールのヒアルロン酸産生促進能を飛躍的に増強し得ることが実証された。
また、レチノールとダイズサーモリシン分解物とを組み合わせることにより得られるヒアルロン酸産生促進作用は、相乗効果的に著しく高いものであることも同時に認められた。
This result shows that hyaluronic acid production is significantly increased in cells cultured in a culture solution containing both retinol and soybean thermolysin degradation product, compared to when cultured in a retinol-only culture solution. It was demonstrated that the degradation product obtained by treating with protease can remarkably enhance the ability of retinol to promote hyaluronic acid production.
It was also recognized that the hyaluronic acid production promoting action obtained by combining retinol and soybean thermolysin degradation product was synergistically remarkably high.
さらに培養液を採取した後の細胞についてWST−1法により生細胞数を計測した。より詳細には、400μl培地中10μlの割合でWST−1試薬を添加したものに培地交換し、次いで45分間培養後、その上清を200μl分取し吸光度を測定した。その結果、レチノールとダイズサーモリシン分解物とを併用した培養液で培養されることによる生細胞数の有意な減少は認められず、生体に対して安全に使用できるものであることが確認された。 Furthermore, the number of viable cells was counted by WST-1 method for the cells after collecting the culture solution. More specifically, the medium was changed to that added with WST-1 reagent at a ratio of 10 μl in 400 μl medium, and after culturing for 45 minutes, 200 μl of the supernatant was taken and the absorbance was measured. As a result, no significant decrease in the number of viable cells was observed by culturing in a culture solution using a combination of retinol and soybean thermolysin degradation product, and it was confirmed that the cells can be safely used for a living body.
実施例3
皮膚線維芽細胞の増殖促進試験
ヒト正常皮膚由来線維芽細胞(NHDF;CRL−2089)を、96ウェルカルチャープレート中で培養した。より詳細には、1280細胞/ウェルの密度でプレートに播種し、37℃で、5%炭酸ガスおよび95%空気の環境下で24時間培養を行った。培養液は、Dulbecco’s Modified Eagle Medium(DMEM)に牛胎仔血清(FBS)を10重量%の濃度で含有した培地を各ウェル200μlずつ使用した。次いで、上記培養液からFBSを抜いた無血清培地に交換し、さらに24時間培養した。その後、培養液を除去し、下記の表2に示す被験薬をそれぞれの濃度で溶解した200μlの無血清培地に交換して培養した(なお、レチノール類は脂溶性のため、先ず無水エタノールで200倍濃度に調整した後、そのエタノール溶液を200μl中1μl添加することで調整を行った)。一方、レチノールもダイズサーモリシン分解物も添加しない無血清培地を200μl添加したものをコントロールとして用いた。さらに48時間培養した後、WST−1法よりも高感度のWST−8法にて各ウェル中の生細胞数を計測した(Cell Counting Kit−8;(株)同仁化学研究所製)。測定結果をもとに、コントロールにおける生細胞数を100%として、各被験薬添加群の生細胞数(%)を算出した。この結果を表2に纏める。
Skin fibroblast proliferation promotion test Human normal skin-derived fibroblasts (NHDF; CRL-2089) were cultured in 96-well culture plates. More specifically, the cells were seeded at a density of 1280 cells / well and cultured at 37 ° C. in an environment of 5% carbon dioxide and 95% air for 24 hours. As the culture solution, 200 μl of a medium containing 10% by weight of fetal bovine serum (FBS) in Dulbecco's Modified Eagle Medium (DMEM) was used. Subsequently, the culture medium was replaced with a serum-free medium from which FBS was removed, and further cultured for 24 hours. Thereafter, the culture broth was removed, and the test drugs shown in Table 2 below were replaced with 200 μl of serum-free medium dissolved at the respective concentrations, and cultured (retinols were first dissolved in absolute ethanol with 200 because they are fat-soluble. After adjusting to a double concentration, the ethanol solution was adjusted by adding 1 μl of 200 μl). On the other hand, 200 μl of serum-free medium to which neither retinol nor soybean thermolysin degradation product was added was used as a control. After further culturing for 48 hours, the number of viable cells in each well was measured by the WST-8 method having higher sensitivity than the WST-1 method (Cell Counting Kit-8; manufactured by Dojindo Laboratories). Based on the measurement results, the number of living cells (%) in each test drug addition group was calculated with the number of living cells in the control as 100%. The results are summarized in Table 2.
この結果から、レチノールとダイズサーモリシン分解物とを併用した培養液で培養した場合には、それぞれを単独で用いて培養する場合と比較して、線維芽細胞数が相乗的に増加することが認められた。 From these results, it was confirmed that the number of fibroblasts increased synergistically when cultured in a culture solution containing both retinol and soybean thermolysin degradation product, compared to the case where each was cultured alone. It was.
以下に製剤実施例を挙げるが、本発明はこれらの実施例に限られるものではない。 Formulation examples are given below, but the present invention is not limited to these examples.
製剤実施例1:乳液
〔成分〕 〔比率〕
全トランスレチノール 0.07g
ダイズタンパク質のサーモリシン分解物(平均分子量1500) 0.5g
スクワラン 2.0g
ダイズ油 0.6g
流動パラフィン 5.0g
セタノール 0.5g
モノステアリン酸グリセリル 2.0g
POE(25)セチルエーテル 2.0g
グリセリン 4.0g
1,3-ブチレングリコール 6.0g
pH調整剤 適量
防腐剤 適量
香料 適量
精製水 適量
100.0g
Formulation Example 1: Emulsion [component] [ratio]
All-trans retinol 0.07g
Thermolysin degradation product of soybean protein (average molecular weight 1500) 0.5g
Squalane 2.0g
Soybean oil 0.6g
Liquid paraffin 5.0g
Cetanol 0.5g
Glyceryl monostearate 2.0g
POE (25) cetyl ether 2.0g
Glycerin 4.0g
1,3-butylene glycol 6.0 g
pH adjuster appropriate amount preservative appropriate amount perfume appropriate amount
Purified water
100.0g
製剤実施例2:クリーム
〔成分〕 〔比率〕
パルミチン酸レチノール 0.14g
ダイズタンパク質のサーモリシン分解物(平均分子量1500) 1.0g
ワセリン 1.0g
スクワラン 5.0g
ヒマワリ油 0.1g
流動パラフィン 10.0g
ステアリン酸 1.5g
ステアリルアルコール 2.0g
モノステアリン酸グリセリル 2.0g
POE(20)セチルエーテル 3.0g
グリセリン 6.0g
1,3-ブチレングリコール 8.0g
ジブチルヒドロキシトルエン 0.1g
pH調整剤 適量
防腐剤 適量
香料 適量
精製水 適量
100.0g
Formulation Example 2: Cream [ingredients] [Ratio]
Retinol palmitate 0.14g
Thermolysin degradation product of soybean protein (average molecular weight 1500) 1.0g
Vaseline 1.0g
Squalane 5.0g
Sunflower oil 0.1g
Liquid paraffin 10.0g
Stearic acid 1.5g
Stearyl alcohol 2.0g
Glyceryl monostearate 2.0g
POE (20) cetyl ether 3.0g
Glycerin 6.0g
1,3-butylene glycol 8.0g
Dibutylhydroxytoluene 0.1g
pH adjuster appropriate amount preservative appropriate amount perfume appropriate amount
Purified water
100.0g
製剤実施例3:クリーム
〔成分〕 〔比率〕
δ−トコフェリルレチノエート 0.1g
ダイズタンパク質のサーモリシン分解物(平均分子量1500) 0.1g
グリセリン 6.0g
トリ(カプリル酸/カプリン酸)グリセリル 0.9g
カルボキシビニルポリマー 0.8g
ポリオキシエチレンセチルエーテル 3.5g
モノステアリン酸グリセリン 3.5g
セタノール 3.0g
ジブチルヒドロキシトルエン 0.03g
pH調整剤 適量
防腐剤 適量
香料 適量
精製水 適量
100.0g
Formulation Example 3: Cream [ingredients] [Ratio]
δ-Tocopheryl retinoate 0.1 g
Thermolysin degradation product of soybean protein (average molecular weight 1500) 0.1g
Glycerin 6.0g
Tri (caprylic acid / capric acid) glyceryl 0.9g
Carboxy vinyl polymer 0.8g
Polyoxyethylene cetyl ether 3.5g
3.5 g of glyceryl monostearate
Cetanol 3.0g
Dibutylhydroxytoluene 0.03g
pH adjuster appropriate amount preservative appropriate amount perfume appropriate amount
Purified water
100.0g
製剤実施例4:クリーム
〔成分〕 〔比率〕
δ−トコフェリルレチノエート 0.25g
ダイズタンパク質のサーモリシン分解物(平均分子量1500) 0.1g
グリセリン 6.0g
トリ(カプリル酸/カプリン酸)グリセリル 2.25g
カルボキシビニルポリマー 0.8g
ポリオキシエチレンセチルエーテル 3.5g
モノステアリン酸グリセリン 3.5g
セタノール 3.0g
ジブチルヒドロキシトルエン 0.03g
pH調整剤 適量
防腐剤 適量
香料 適量
精製水 適量
100.0g
Formulation Example 4: Cream [ingredients] [Ratio]
δ-Tocopheryl retinoate 0.25g
Thermolysin degradation product of soybean protein (average molecular weight 1500) 0.1g
Glycerin 6.0g
Tri (caprylic / capric) glyceryl 2.25g
Carboxy vinyl polymer 0.8g
Polyoxyethylene cetyl ether 3.5g
3.5 g of glyceryl monostearate
Cetanol 3.0g
Dibutylhydroxytoluene 0.03g
pH adjuster appropriate amount preservative appropriate amount perfume appropriate amount
Purified water
100.0g
製剤実施例5:内服用錠剤(1錠中)
〔成分〕 〔比率〕
全トランスレチノール 0.05mg
ダイズタンパク質のサーモリシン分解物(平均分子量1500)50.0mg
ビタミンB1 1.0mg
ビタミンB2 0.5mg
香料 0.625mg
甘味料 0.625mg
ショ糖脂肪酸エステル 3.75mg
マルチトール 68.45mg
125.0mg
Formulation Example 5: Tablets for internal use (in 1 tablet)
[Ingredient] [Ratio]
Total trans-retinol 0.05mg
Soybean protein thermolysin degradation product (average molecular weight 1500) 50.0mg
Vitamin B1 1.0mg
Vitamin B2 0.5mg
Fragrance 0.625mg
Sweetener 0.625mg
Sucrose fatty acid ester 3.75mg
Maltitol 68.45mg
125.0mg
Claims (3)
(B)ダイズタンパク質のサーモリシン分解物
とを含有する組成物。 (A) at least one selected from the group consisting of retinol and derivatives thereof;
(B) A composition containing a thermolysin degradation product of soybean protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007165686A JP5118399B2 (en) | 2006-06-23 | 2007-06-22 | Composition having hyaluronic acid production promoting ability and / or fibroblast proliferation promoting ability |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006174626 | 2006-06-23 | ||
JP2006174626 | 2006-06-23 | ||
JP2007165686A JP5118399B2 (en) | 2006-06-23 | 2007-06-22 | Composition having hyaluronic acid production promoting ability and / or fibroblast proliferation promoting ability |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008024704A true JP2008024704A (en) | 2008-02-07 |
JP5118399B2 JP5118399B2 (en) | 2013-01-16 |
Family
ID=39115706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007165686A Expired - Fee Related JP5118399B2 (en) | 2006-06-23 | 2007-06-22 | Composition having hyaluronic acid production promoting ability and / or fibroblast proliferation promoting ability |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5118399B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008024703A (en) * | 2006-06-23 | 2008-02-07 | Rohto Pharmaceut Co Ltd | Composition having collagen production-promoting ability and/or fibroblast proliferation-promoting ability |
JP2009079043A (en) * | 2007-09-04 | 2009-04-16 | Rohto Pharmaceut Co Ltd | Composition having fibroblast proliferation promoting ability |
JP2010270062A (en) * | 2009-05-21 | 2010-12-02 | Pias Arise Kk | Hyaluronic acid-degrading enzyme inhibitor in skin, hyaluronic acid-enhancing composition in skin, and topical skin preparation and cosmetic containing the hyaluronic acid-degrading enzyme inhibitor or hyaluronic acid-enhancing composition |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873338A (en) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | Skin external preparation |
JP2000256394A (en) * | 1999-03-15 | 2000-09-19 | Rheology Kino Shokuhin Kenkyusho:Kk | Method for producing bioactive peptide composition |
JP2002187838A (en) * | 2000-12-19 | 2002-07-05 | Yakult Honsha Co Ltd | External preparation for skin |
JP2002284647A (en) * | 2001-03-26 | 2002-10-03 | Cosmo Products Kk | Hair restorer |
JP2002284662A (en) * | 2001-03-27 | 2002-10-03 | Kanebo Ltd | Composition for external skin preparation |
JP2004075629A (en) * | 2002-08-21 | 2004-03-11 | Kanebo Ltd | Cosmetic |
JP2004091397A (en) * | 2002-08-30 | 2004-03-25 | Fancl Corp | A composition for preventing skin aging that prevents, prevents and improves flattening of the epidermis |
JP2004189644A (en) * | 2002-12-10 | 2004-07-08 | Kanebo Ltd | Cosmetic |
JP2004339139A (en) * | 2003-05-15 | 2004-12-02 | Kanebo Ltd | Skin cosmetic |
JP2006096747A (en) * | 2004-08-31 | 2006-04-13 | Nichiro Corp | Salmon-derived angiotensin I converting enzyme-inhibiting peptide compound or peptide composition containing the same and method for producing them |
WO2007049400A1 (en) * | 2005-10-24 | 2007-05-03 | Rohto Pharmaceutical Co., Ltd. | Composition for promoting the production of collagen and/or hyaluronic acid |
WO2007148804A1 (en) * | 2006-06-23 | 2007-12-27 | Rohto Pharmaceutical Co., Ltd. | Composition capable of promoting the production of hyaluronic acid |
WO2007148803A1 (en) * | 2006-06-23 | 2007-12-27 | Rohto Pharmaceutical Co., Ltd. | Composition capable of promoting the production of hyaluronic acid |
-
2007
- 2007-06-22 JP JP2007165686A patent/JP5118399B2/en not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873338A (en) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | Skin external preparation |
JP2000256394A (en) * | 1999-03-15 | 2000-09-19 | Rheology Kino Shokuhin Kenkyusho:Kk | Method for producing bioactive peptide composition |
JP2002187838A (en) * | 2000-12-19 | 2002-07-05 | Yakult Honsha Co Ltd | External preparation for skin |
JP2002284647A (en) * | 2001-03-26 | 2002-10-03 | Cosmo Products Kk | Hair restorer |
JP2002284662A (en) * | 2001-03-27 | 2002-10-03 | Kanebo Ltd | Composition for external skin preparation |
JP2004075629A (en) * | 2002-08-21 | 2004-03-11 | Kanebo Ltd | Cosmetic |
JP2004091397A (en) * | 2002-08-30 | 2004-03-25 | Fancl Corp | A composition for preventing skin aging that prevents, prevents and improves flattening of the epidermis |
JP2004189644A (en) * | 2002-12-10 | 2004-07-08 | Kanebo Ltd | Cosmetic |
JP2004339139A (en) * | 2003-05-15 | 2004-12-02 | Kanebo Ltd | Skin cosmetic |
JP2006096747A (en) * | 2004-08-31 | 2006-04-13 | Nichiro Corp | Salmon-derived angiotensin I converting enzyme-inhibiting peptide compound or peptide composition containing the same and method for producing them |
WO2007049400A1 (en) * | 2005-10-24 | 2007-05-03 | Rohto Pharmaceutical Co., Ltd. | Composition for promoting the production of collagen and/or hyaluronic acid |
WO2007148804A1 (en) * | 2006-06-23 | 2007-12-27 | Rohto Pharmaceutical Co., Ltd. | Composition capable of promoting the production of hyaluronic acid |
WO2007148803A1 (en) * | 2006-06-23 | 2007-12-27 | Rohto Pharmaceutical Co., Ltd. | Composition capable of promoting the production of hyaluronic acid |
Non-Patent Citations (2)
Title |
---|
CSNC200801396019; FRAGRANCE JOURNAL Vol.33, No.10 p.95-100 (2005-10) * |
JPN6011069324; FRAGRANCE JOURNAL Vol.33, No.10 p.95-100 (2005-10) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008024703A (en) * | 2006-06-23 | 2008-02-07 | Rohto Pharmaceut Co Ltd | Composition having collagen production-promoting ability and/or fibroblast proliferation-promoting ability |
JP2009079043A (en) * | 2007-09-04 | 2009-04-16 | Rohto Pharmaceut Co Ltd | Composition having fibroblast proliferation promoting ability |
JP2010270062A (en) * | 2009-05-21 | 2010-12-02 | Pias Arise Kk | Hyaluronic acid-degrading enzyme inhibitor in skin, hyaluronic acid-enhancing composition in skin, and topical skin preparation and cosmetic containing the hyaluronic acid-degrading enzyme inhibitor or hyaluronic acid-enhancing composition |
Also Published As
Publication number | Publication date |
---|---|
JP5118399B2 (en) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5084393B2 (en) | Composition having collagen production promoting ability and / or fibroblast proliferation promoting ability | |
JP5018171B2 (en) | Plant-derived activator and extracellular matrix production promoter | |
JP5011121B2 (en) | Composition for promoting collagen and / or hyaluronic acid production | |
WO2011129374A1 (en) | Composition for external use for complexion improvement | |
JP6537559B2 (en) | Hyaluronic acid-containing emulsion composition | |
JP2010132639A (en) | Dna damage inhibitor and matrix metalloprotease-1 production inhibitor | |
JP2009161458A (en) | Incorporation promoter of ascorbic acids into cell | |
CN108057117B (en) | Use of a composition comprising collagen hydrolysate | |
JP5468757B2 (en) | Composition having fibroblast proliferation promoting ability | |
JP5241054B2 (en) | Composition for promoting collagen synthesis | |
JP4950571B2 (en) | Composition having ability to promote collagen production | |
JP2005306831A (en) | Skin preparation | |
JP2008074788A (en) | Elastin production promoter | |
JP5054006B2 (en) | Composition having hyaluronic acid production promoting ability | |
JP5118398B2 (en) | Composition having collagen production promoting ability and / or fibroblast proliferation promoting ability | |
JP5118399B2 (en) | Composition having hyaluronic acid production promoting ability and / or fibroblast proliferation promoting ability | |
JP2007230921A (en) | External preparation for skin | |
JP2005263794A (en) | Collagen synthesis acceleration composition | |
KR102537101B1 (en) | NANO EMULSION COMPOSITION COMPRISING Squalene, COSMETIC COMPOSITION COMPRISING THE SAME, AND METHOD FOR PREPARING SAME | |
JP4993890B2 (en) | Topical skin preparation | |
JP5578160B2 (en) | Plant-derived activator and extracellular matrix production promoter | |
JP2007284430A (en) | Glutathione production promoting agent | |
JP2006265120A (en) | Collagen synthesis promoter | |
JP2005015387A (en) | Antioxidative composition | |
JP5520703B2 (en) | Composition for promoting collagen synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120131 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20120131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120308 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120920 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121016 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121019 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151026 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151026 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |